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THE ROLE OF NICOTINE, a7 NICOTINIC ACETYLCHOLINE RECEPTORS 
AND EXTRACELLULAR MATRIX REMODELING IN PULMONARY FIBROSIS 
 
Glenn Ward Vicary 
 
November 22nd, 2016 
 
The median survival for idiopathic pulmonary fibrosis (IPF) patients from 
diagnosis is a dismal 3 years. This condition is characterized by pulmonary 
fibroproliferation and excess production and disordered deposition of extracellular 
matrix (ECM) proteins resulting in obliteration of the original tissue architecture, 
loss of lung function and eventual death due to respiratory failure.  
The main hindrance to the development of effective treatments against 
pulmonary fibrosis is the late detection of its progression and is often of unknown 
cause. Tobacco smoke represents the most important environmental factor linked 
to the development of pulmonary fibrosis, with over 60% of IPF patients current or 
ex-smokers, yet exactly how tobacco influences lung injury and repair is unknown. 
Research in this area has been hampered by the fact that tobacco is a very
	 vii	
complex substance, containing thousands of chemicals. Due to this complexity, I 
have pursued a different approach and focused on factors, specifically nicotine, 
which might render the lung susceptible to fibrosis and contribute to the early 
pathophysiology of IPF. 
In this dissertation, I extend the work of Dr. Jesse Roman’s lab to investigate 
additional extracellular matrix modifications via nicotine exposure, including 
collagen type I. Investigating the cellular receptors and molecular mechanisms 
mediating the effects of nicotine on fibroblast collagen production/deposition and 
the potential role of nicotine-induced remodeling in rendering the host susceptible 
to pulmonary fibrosis are explored through 5 chapters: 1) The effects of nicotine 
on lung fibroblast proliferation and collagen expression/deposition in vitro and in 
vivo, and the cholinergic receptors responsible for these effects. 2) The effects of 
chronic nicotine exposure on injury-induced fibrosis. 3) The impact of chronic 
nicotine exposure on survival after bleomycin-lung injury. 4) A new diagnostic 
physiological formula for earlier detection of pulmonary fibrosis progression in IPF 
patients. 5) A clinical review on Hermansky-Pudlak syndrome, an orphan disease 
characterized by the natural formation of pulmonary fibrosis. This work provides a 
detailed understanding of the mechanisms by which tobacco promotes lung 
remodeling, leading to the development of better tools for diagnostic tracking, care 
and treatment of these patients.   
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BACKGROUND AND INTRODUCTION 
 
1.1 Overview  
 
The lung is a dynamic organ, constantly expanding and contracting while 
being exposed to environmental and chemical challenges. To handle these insults, 
the lung readily repairs itself against a range of antigens and environmental 
pathogens. Correct lung repair allows for normal lung function, but when disrepair 
occurs, a variety of diseases can occur, including idiopathic pulmonary fibrosis. 
Lung remodeling caused by disrepair is often drastic, affecting protein composition, 
lung structure, elasticity, and oxygen diffusion, making it progressively difficult for 
patients to do even basic activities such as walking and talking.  
 
1.2 Prevalence of Idiopathic Pulmonary Fibrosis (IPF) 
 
Idiopathic pulmonary fibrosis (IPF) is a chronic disease that affects over 
100,000 Americans [1]. The median survival for patients from diagnosis is a dismal
	 2	
 3 years [2]. IPF is usually diagnosed in older patients, with more than 85% of 
patients over 50 years old and an increased prevalence in males [2-9]. 
Surprisingly, the number of IPF cases appears to be increasing; likely due to the 
aging population, increased patient and physician awareness of IPF and improved 
computerized tomography (CT) imaging [10].  
IPF is classified as an interstitial lung disease (ILD), which is an umbrella 
term for a large group of pulmonary disorders characterized by progressive 
remodeling of pulmonary tissue. ILDs are characterized by known and unknown 
causes, consisting of over 200 diseases including sarcoidosis and idiopathic 
interstitial pneumonias (IIPs). IIPs are subclassified based on histological 
appearance, with the most common and severe form of IIP being IPF; which 
accounts for 20-30% of ILDs (Figure 1) [11, 12]. IPF is diagnosed by exclusion of 
other diseases when there is evidence of impairment of lung function and presence 
of a histopathological pattern of usual interstitial pneumonia (UIP). 
 
1.3 Causes of IPF 
 
Environmental factors (e.g., allergens, tobacco), occupational exposures 
(e.g. asbestos and silica exposure), genetic factors (e.g. surfactant-related 
proteins, telomerase, HPS) and viral factors (herpesvirus) have been associated 




Figure 1. Classifying Interstitial Lung Diseases 
Reprinted with permission from Nature Publishing Group. [Nat Rev Drug Discover] (du Bois, R.M., Strategies for treating 
idiopathic pulmonary fibrosis, 2010. 9, p. 124-140) Copyright 2010 
License #: 3972681241289 
 
Idiopathic pulmonary fibrosis is classified as an interstitial lung disease, which is 
an umbrella term for a large group of pulmonary disorders characterized by 
progressive remodeling of pulmonary tissue. Interstitial lung diseases can be 
subdivided into four broad categories based on histological appearance. Idiopathic 
pulmonary fibrosis is the most lethal ILD and its diagnosis depends on the 
exclusion of other diseases. 
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Underlying amplifying factors like aging and epigenetic changes are thought to 
influence the progressive nature of pulmonary fibrosis [18]. Most cases of IPF are 
sporadic with 4% of patients being familial [19-22]. The familial form of IPF tends 
to present at a younger age when compared with the more common idiopathic 
form.  
 
1.4 Tobacco and Nicotine  
 
Of all the environmental risk factors, tobacco smoke represents a major 
factor linked to the development of IPF, with over 60% of IPF patients being current 
or ex-smokers [1, 23-25]. However, studying the role of tobacco in IPF has been 
hampered by the complex nature of tobacco smoke, which contains over 7,000 
chemicals [26, 27]. Due to the complexity of tobacco, attention has recently turned 
to the potential role of nicotine in mediating the effects of tobacco smoke.  
Nicotine is an alkaloid present in tobacco and represents ~0.6–3.0% of the 
dry weight of tobacco and is known for driving the addictiveness of cigarettes. 
Nicotine’s unique properties allow 30% of it to be instantly absorbed and reach the 
brain within 7 seconds [28, 29]. Studies have shown smokers to have average 
nicotine levels of 10-50 ng/ml (0.3 µM) in blood plasma [30]. The metabolism of 
nicotine varies between species, with a plasma half-life of 2 hours in humans and 
approximately 6-7 minutes in mice [30]. In humans, the metabolism rate of nicotine 
is affected by age, race, and gender. Women and younger smokers have been 
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reported to metabolize nicotine quicker [31, 32]. Additionally, caucasians cleared 
nicotine more rapidly than Asians and African Americans [30]. 
Nicotine not only drives addiction, but affects several biological processes, 
including cell proliferation, apoptosis, migration, invasion, angiogenesis, 
inflammation and immunity [33]. Additional studies have unveiled that nicotine also 
affects lung development through increased branching and increasing nAChR 
expression [34, 35]. Thus, it appears that nicotine is not just responsible for 
tobacco dependence, but might also contribute to the pathogenesis of tobacco-
related disorders, including IPF.   
 
1.5 Mechanisms of Idiopathic Pulmonary Fibrosis 
 
The exact mechanisms which contribute to the development of IPF are 
unknown. However, current models of pulmonary fibrosis pathogenesis indicate 
epithelial cell apoptosis and dysfunction, likely type I alveolar epithelial cells 
(AECs), as the inciting cause of IPF [36]. Type I AECs are believed to control 
pulmonary structural mesenchymal cells through the secretion of various 
mediators and cell–cell contact [37]. When injured, type I AECs are thought to 
signal type II AECs to undergo hyperplastic proliferation to cover the exposed 
basement membranes. After normal repair, the hyperplastic type II AECs will 
undergo regulated apoptosis and any remaining cells will differentiate to become 
type I AEC [38-40]. In contrast, disrepair leads to scar tissue formation, which is 
usually self-limited, but can become progressive, with ongoing lung parenchymal 
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destruction and replacement by pathologic fibrosis with the activation of fibroblasts 
(Figure 2).  
Under these conditions of disrepair, Transforming Growth Factor-b (TGF-
b) stimulation may activate fibroblasts to differentiate into a-smooth muscle actin 
(a-SMA) expressing myofibroblasts [18, 36, 41]. The origins of these fibroblasts 
(myofibroblasts) are unclear, but combinations of mechanisms are hypothesized, 
including the transdifferentiation of epithelial cells (epithelial-mesenchymal 
transformation (EMT)), the differentiation of fibrocytes and stem cells, and the 
proliferation of resident fibroblasts [42-44].  
Regardless of the source of origin, the interplay between dysfunctional 
epithelial cells and activated myofibroblasts seems to drive unrestrained collagen 
deposition and tissue scarring ‘fibrotic foci’, resulting in obliteration of the original 
architecture, loss of lung function and, eventual death due to respiratory failure 
(Figure 3) [45-48]. In IPF patients, areas of AEC apoptosis and foci of a-SMA-
positive myofibroblasts were detected together, consistent with the mechanism 
proposed above [49]. 
 
1.6 Diagnosis and Management of IPF 
 
There is no cure for IPF, so treatment focuses on slowing the progression 
of fibrosis and improving patient quality of life. Avoidance of cigarette smoke and 
other pulmonary irritants is critical with daily exercise recommended to avoid 
deconditioning. Recently, the FDA has approved two drugs for IPF treatment, 
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Pirfenidone and Nintedanib [50-53]. It should be emphasized that these drugs are 
not curative, but instead appear to slow down progression in IPF. Also, the 
effectiveness of these drugs in other conditions resulting in pulmonary fibrosis has 
not been studied, thus, current interventions for pulmonary fibrosis remain 
suboptimal. Pirfenidone is a small molecular TGF-b inhibitor, whereas Nintedanib 
is a tyrosine kinase inhibitor that targets various growth factor receptors including 
platelet derived growth factor (PDGF), fibroblast growth factor (FGFR) and 
vascular endothelial growth factor (VEGF) receptors [50, 52, 54]. These drugs also 
have undesirable side effects, so supportive therapy is an additional approach to 
management of IPF. Additional therapies include supplemental oxygen for 
hypoxemia, pulmonary rehabilitation and lung transplantation in appropriate 
candidates. 
The main hindrance to the development of effective treatments against 
pulmonary fibrosis is due to late diagnosis. For this reason, efforts should be 
directed at novel therapeutics for prevention of lung remodeling or early detection 
through the identification of specific early biomarkers of disease. It is for this 
reason that I have pursued a different approach and focused on the factors 
that render the lung susceptible to fibrosis and contribute to the early 
pathophysiology of IPF, which might help gain insight into the overall 
mechanisms that lead to the development of this disease and the factors that 




Figure 2. Proposed Events of Idiopathic Pulmonary Fibrosis  
Reprinted with permission from The Company of Biologists Ltd. [Dis. Model. Mech.] (Kropski J. A. et Al., Genetic studies 
provide clues on the pathogenesis of idiopathic pulmonary fibrosis, 2013. 6(1): p. 9-17) Copyright 2012 
Reproduction Lic# https://creativecommons.org/licenses/by-nc-sa/3.0 
 
Various genetic factors and environmental exposures produce a ‘vulnerable’ 
alveolar epithelial cell (AEC) population. Exposure to a secondary recurrent or 
persistent injury leads to enhanced AEC apoptosis, as well as aberrant activation 
of stress response pathways. Ongoing type II AEC dysfunction leads to scar 
formation and progressive loss of lung architectural complexity. This culminates 




Figure 3. Fibroblastic Foci in Idiopathic Pulmonary Fibrosis 
Copyright Permissions not required for this type of use. (Lederer, D., A new era in IPF: Diagnosing Idiopathic Pulmonary 
Fibrosis) http://www.pilotforipf.org/ipf-resources/slide-library 
 
Idiopathic pulmonary fibrosis is characterized by unrestrained collagen deposition 
and tissue scarring from fibroblasts, forming ‘fibrotic foci’, resulting in obliteration 
of the original extracellular matrix as seen here in histological staining by 




Normal Lungs Pulmonary Fibrosis
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1.7 Lung Extracellular Matrix 
 
Extracellular matrix remodeling is the main characteristic of pulmonary 
fibrosis. The extracellular matrix (ECM) was historically believed to be a non-
cellular scaffolding of fibrous proteins, glycoproteins and proteoglycans for cells to 
adhere, but recent research has shown that the ECM plays many crucial roles in 
homeostasis and disease [55]. Now, the ECM is known to affect important 
biochemical and biomechanical signaling between cells, including cellular 
differentiation [56].  
The pulmonary ECM consists of basement membranes and the interstitial 
spaces. These basement membranes are found under epithelial and endothelial 
cells which form the interstitial spaces of the parenchyma [57]. Within this 
interstitium is where fibroblasts, which are mainly responsible for ECM production, 
reside. The ECM of murine and human lungs have been characterized, showing 
the majority of the matrisome is conserved [58, 59]. Under homeostatic conditions, 
the ECM is tightly regulated for normal development and wound healing. 
Alterations in pulmonary ECM are suspected to play a role in disorders affecting 
all lung compartments (airways, vessels, alveolar units), including IPF, Chronic 
Obstructive Pulmonar Disease (COPD) and sarcoidosis. 
Fibronectin is an ECM glycoprotein highly expressed in injured tissues, and 
is considered a sensitive marker of tissue injury and activation of tissue remodeling 
[60-62]. In the injured lung, fibronectin is deposited over denuded basement 
membranes where it is thought to support the migration of alveolar epithelial cells 
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during repair [61]. It promotes the proliferation of fibroblasts, aids in the deposition 
of collagen, stimulates the chemotaxis of monocytes and other immune cells and 
induces cytokine production in macrophages [63-69]. Excessive fibronectin 
deposition, however, has been hypothesized to promote disrepair [70]. Fibronectin 
expression and fibroproliferation were increased in the lungs of smokers [71-74]. 
Also, clinical studies have shown increased fibronectin content within the 
bronchoalveolar lavage fluid of smokers [75].  
Fibrillar collagen is another matrix component highly expressed in lung  
tissues during injury and repair, and its expression signals activation of more 
permanent tissue remodeling. Collagen type I is the most common form of collagen 
in the human body and is highly abundant within connective tissues, including 
tendon, ligament, skin, and lung tissue. Each rope-like procollagen molecule is 
made up of three chains: two pro-α1 (I) chains, which are produced from 
the COL1A1 gene, and one pro-α2 (I) chain, which is produced from the 
COL1A2 gene. After processing, the resulting mature collagen molecules arrange 
themselves into long, thin fibrils. Individual collagen molecules are then cross-
linked to one another within these fibrils, thereby forming strong collagen fibrils 
[76].  
These ECM proteins, together with proteoglycans and other matrix 
components compose the acellular structure of the lung. The controlled deposition 
and turnover of these ECM proteins is essential for maintaining tissue integrity. 
Alterations in these processes lead to aberrant tissue remodeling and fibrotic lung 
diseases. 
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1.8 Transitional Remodeling 
 
The connection between nicotine and tissue remodeling seen in pulmonary 
fibrosis has yet to be completely elucidated. To date, there are no data suggesting 
nicotine, alone, can promote pulmonary fibrosis. The Roman lab has previously 
shown that nicotine exposure induces fibronectin deposition by pulmonary 
fibroblasts. Additionally, increased fibronectin deposition was detected in the lungs 
of animals chronically exposed to nicotine, but without overt alterations in overall 
lung architecture [77].  
Instead, this dissertation provides evidence of a process termed transitional 
remodeling, which might precede the dramatic tissue alterations and potentiate 
pulmonary fibrosis progression. Transitional remodeling is defined as subtle 
alterations in the ECM composition deposition and assembly, including fibronectin 
and collagen, without causing overt change in tissue architecture. Nicotine 
exposure induces transitional remodeling, but this could be reversible and, in fact, 
in most injuries, the body may undergo transitional remodeling as part of the 
normal wound healing process. As such, the body returns to normal. However, the 
implications of transitional remodeling in disrepair are not fully understood. If the 
lung experiences a second hit (e.g. bleomycin), transitional remodeling may render 
the host susceptible to disrepair through the pro-inflammatory effects of matrix 
fragments and by its ability to promote the deposition of other more permanent 
ECM proteins (Figure 4) [78]. 
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1.9 Nicotinic Acetylcholine Receptors (nAChRs) in Lungs 
 
As presented above, nicotine promotes transitional remodeling. However, 
the mechanisms involved in this process are unclear. Nicotine interacts with the 
body through receptors capable of signal transduction termed nicotinic 
acetylcholine receptors (nAChRs) (Figure 5) [79, 80]. nAChRs are a family of 
multimeric acetylcholine-triggered cation channel proteins that form the excitatory 
neurotransmitter receptors on muscles and nerves in the peripheral nervous 
system. In addition to the nervous system, nAChRs have been found in 
lymphocytes [81], leukocytes [82], monocytes [83], keratinocytes [84], and NIH3T3 
fibroblasts [85]. These receptors are pentameters made up in homomeric and 
heteromeric fashion. The homomeric (a7)5 is the most common nAChR, containing 
five a7 subunits and is the most abundant homomeric form in the body. Binding of 
a ligand (acetylcholine/nicotine) leads to depolarization of the membrane and 
generation of an action potential that spreads along the surface of cell membranes.  
Evidence of a3, a5, a7 nAChR subunits has been detected in both human 
and mouse bronchial epithelial cells [86]. a7 nAChRs have been detected in airway 
epithelial cells of developing primate lungs around large airways and blood 
vessels, free alveolar macrophages, alveolar type II cells and pulmonary 




Figure 4. Transitional Remodeling of the Lung Extracellular Matrix (ECM) 
 
Copyright Permissions not required for this type of use. (Adapted from Poole, L. and Arteel, G., Transitional Remodeling 
of the Hepatic Extracellular Matrix in Alcohol-induced Liver Injury) https://www.hindawi.com/journals/bmri/aip/3162670/ 
 
Nicotine exposure induces ECM proteins and subclinical remodeling forming a 
transitional extracellular matrix. This transitional matrix, while it causes no 
detrimental changes in the lung, may contribute to disrepair and inflammation after 
injury. If the insult is removed, the transitional matrix may resolve back to a normal 
state. Exposure to a secondary injury may progress to a fibrotic matrix via 
















Figure 5. Structure of Nicotinic Acetylcholine Receptors 
Reprinted with permission from Nature Publishing Group. [Oncogene] (Improgo, M.R., From smoking to lung cancer: the 
CHRNA5/A3/B4, 2010. 29, p. 4874-4884) Copyright 2010 
License #: 3991471282111 
 
Nicotinic Acetylcholine Receptors (nAChRs) are a family of multimeric 
acetylcholine-triggered cation channel proteins that form the excitatory 
neurotransmitter receptors on muscles and nerves in the peripheral nervous 
system. (A) Schematic representation illustrating the pentameric arrangement of 
subunits in an assembled nAChR. (B) Conserved domains of a nAChR subunit 
including the amino (N) and carboxy (C) terminals, transmembrane segments 
(M1–M4) and the intracellular loop. (C) Assembly of heteromeric and homomeric 
nAChR subtypes. Individual nAChR subunits are represented as colored circles, 
with diamonds representing ligand-binding sites. Pentagons in the center of each 
pentamer represent the pore region, which is selective for cations (e.g. Calcium).  
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The role of nAChRs in the lung is largely unknown. Acetylcholine is 
produced by several non-neuronal lung cells as a regulator of bronchomotor tone 
and mucus secretion from airway submucosal glands in lungs. Nicotine-nAChR 
interactions can affect lung development and ECM deposition. Dr. Roman’s lab 
has demonstrated that nicotine induces fibronectin expression in lung fibroblasts 
via a7 nAChRs [77]. This increase in matrix proteins suggests that nicotine might 
induce myofibroblastic features in lung fibroblasts, which has been associated with 
pulmonary fibrosis [87]. Dr. Elliot Spindel’s group has published articles showing 
a7 nAChR expression was increased in animals exposed to nicotine, correlating 
with increased tissue remodeling (collagen deposition) in surrounding large 
airways and vessels [77, 88-94]. Nicotine-a7 nAChR interactions also influence 
lung branching morphogenesis and result in airway thickening and dysfunction [34, 
35, 91].  
 
1.10 The Role of MEK-1/Erk pathway in mediating nAChR signaling 
 
 The intracellular pathways by which nicotine-nAChR interactions promote 
lung tissue remodeling are not fully characterized. Fibroblasts from IPF patients 
show sustained mitogen-activated protein kinase (MAPK) induction and activation, 
a downstream target of the MEK-1/Erk pathway [95, 96]. Fibrotic agents, like 
crystalline silica and asbestos, promote activation of MEK-1, which increases the 
level of pro-inflammatory cytokines [97]. MEK-1/Erk also induces tumor necrosis 
factor-a (TNF-a) through the pro-fibrotic growth factor TGF-b [98].  
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As a proof of concept for clinical targeting, a MEK inhibitor prevented TNF-
a induction and even reversed existing TGF-b-induced lung fibrosis [99]. 
Additionally, a different MAPK/Erk inhibitor prevented bleomycin-induced fibrosis 
[100]. No studies have been published on the effects of MEK-1 inhibition in 
humans. MEK-1/Erk could provide a future clinical target for preventing nicotine 
induced lung changes. 
 
1.11 Nicotine and Inflammation 
 
In addition to ECM, the regulation of the immune system is a critical 
physiological process during pulmonary development, healing, trauma, or 
infection. Controlled production of cytokines, such as interleukins (ILs) and TNF-a 
induce beneficial inflammatory responses that promote local coagulation to confine 
infection and tissue damage [101]. However, unrestricted production of these 
cytokines can cause more damage than the original injury.  
Acetylcholine is an important neurotransmitter that controls the production 
of pro-inflammatory cytokines. Acetylcholine (endogenous) and nicotine 
(exogenous) can either bind to muscarinic receptors, which are G-protein-coupled 
receptors, or nAChRs, which are ligand-gated ion channels [102].  
How nicotine affects inflammation is still being elucidated. nAChRs are 
believed to induce different inflammatory responses based on receptor affinities in 
multiple immune cell types [103-107]. a7 nAChR ligands (acetylcholine and 
nicotine) are normally considered anti-inflammatory due to activation of the 
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cholinergic anti-inflammatory pathway. Nicotine has been shown to reduce pro-
inflammatory cytokine expression in monocytes [108]. Interestingly, nicotine is 
more specific than acetylcholine at inhibiting the production of pro-inflammatory 
cytokines from macrophages and monocytes and this appears to be a7 nAChR 
specific [101, 109-111]. Additionally, an a7 agonist PNU-282987 was used in a 
murine model of LPS-induced acute lung injury reduced neutrophil recruitment and 
IL- 1b, TNF-a, IL-6 and IL-10 cytokine levels in the bronchoalveolar lavage fluid. 
In addition, the frequency of M1 macrophages suggests a change in the 
macrophage profile [112]. Nicotine can also affect immune cell function, inhibiting 
phagocytic activity in neutrophils while enhancing neutrophil elastase release 
without affecting superoxide production [113, 114]. Additionally, nicotine induces 
neutrophil traps, which can contribute to tissue damage and inflammation [115]. 
Thus, nicotine-a7 nAChR interactions appears to directly decrease inflammation 
in certain cells, but systemic exposure and indirection activation still need to be 
investigated.  
 
1.12 Fibrosis and Inflammation 
 
 Pulmonary fibrosis has traditionally been considered related to extensive 
ECM remodeling with subdued inflammation, but more recent research connects 
innate and adaptive immune responses to fibrogenesis. TGF-b1 is considered a 
central mediator in pulmonary fibrosis and is the most studied soluble mediator in 
addition to playing a central role in promoting EMT [116, 117]. Additionally, 
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activated fibroblasts are highly responsive to additional growth factors/pro-
inflammatory cytokines (IL-1b, IL-6, IL-13, IL-33, TNF-a, and interferon-g (IFN-g)) 
which enhance TGF-b1-induced EMT [118, 119]. IL-1b is a primary inflammasome 
cytokine produced by a variety of cells, including activated macrophages, dendritic 
cells, neutrophils, and epithelial cells and fibroblasts. It has been shown to 
contribute to the progression of adenoviral-induced pulmonary fibrosis and 
bleomycin-induced pulmonary fibrosis [120, 121].  
Although several cytokines have been associated with IPF progression, the 
involvement of each individual immune cells is more complex. Recent studies have 
re-ignited the interest into the potential role of inflammation in lung fibrosis and 
have implicated t cells, neutrophils, alveolar macrophages, and other cells capable 
of releasing the important cytokine regulating mediators, potentially regulating IPF 
progression (IFN-g, IL-2, TNF-b, IL-4, IL-5, IL-6, IL-9, IL10, IL-13) [122-128]. 
In addition to cytokines and soluble mediators, immune cells and fibroblasts 
can alternatively be activated by integrins, which can directly interact with the ECM 
[129]. Some integrins include aIIbb3 (fibrinogen receptor), aVb3 (vitronectin 
receptor), a2b1 (collagen receptor), a5b1 (fibronectin receptor), and a6b1 (laminin 
receptor) [130]. This dissertation focuses mainly on collagen type I, because type 
I makes up 90% of all collagen in the body. The a2b1 integrin is the main receptor 
that interacts with collagen [131, 132]. Collagen has been found to induce M2 
macrophages (Th2 response), feeding a feedback loop between fibroblasts and 
macrophages, promoting fibrotic responses to lung injury [133-135]. Expression 
levels of integrins also seems to play a role in fibroblastic response, with low a2b1 
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In the lung, another line of protection against the constant exposure to 
environmental chemicals and oxidants is a high concentration of anti-oxidants. 
When the tightly regulated balance of oxidants and anti-oxidants becomes altered, 
this state is referred to as oxidative stress [137]. Oxidant stress can be generated 
through many pathways including the generation of nitrogen and reactive oxygen 
species (ROS), alterations in Nox expression, and mitochondrial dysfunction [138]. 
ROS include superoxide, hydrogen peroxide and hydroxyl radicals, and cause 
unspecific damage to cells and extracellular matrix [139].  
Anti-oxidants are the main line of defense against oxidative damage in the 
lung (Figure 6). These include superoxide dismutases (SODs), catalase, 
glutathione peroxidase, glutathione S-transferase, and thioredoxin. The SOD 
family catalyzes superoxide radicals into hydrogen peroxide and oxygen in a first 
order reaction. There are three mammalian SODs: cytosolic (SOD1), mitochondrial 
(SOD2), and extracellular (SOD3) [140-142]. The major intracellular SOD is SOD1, 
which is a 32-kD copper and zinc containing homodimer (also called Cu/Zn SOD) 
present in the cytoplasm and nucleus [143]. SOD2 (MnSOD) contains a 
manganese 93-kD homotetramer and is synthesized in the cytoplasm to be 
translocated to the inner matrix of mitochondria [141, 144]. SOD2 seems to play a 
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role in neurodegenerative diseases [145]. SOD3 (EC-SOD) is the last mammalian 
SOD to be discovered and is primarily extracellular [142].  
Acute and chronic forms of lung injury, including those associated with 
pulmonary fibrosis, are associated with oxidant stress [146]. BAL fluid from IPF 
patients showed increased levels of 8-isoprostane, a biomarker of oxidative stress 
[147]. Additionally, higher levels of oxidants (e.g. ELF myeloperoxidase, 
superoxide, hydrogen peroxide, iNOS) were detected in IPF patients, further 
suggesting a role for oxidant stress. [148-150].  
With tobacco smoke being the main risk factor for IPF, some have 
postulated that cigarette smoke might promote tissue fibrosis through the induction 
of oxidant stress, yet the role of nicotine in this process is unclear [146]. In rats, 
nicotine has been shown to affect the oxidative state of the lung by increasing the 
activity of superoxide dismutase, an important protective mechanism in lung [151, 
152]. Overexpression of superoxide dismutase was protective against fibrosis in 
the bleomycin model [153]. 
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Figure 6. Oxidative Stress in IPF 
Reprinted with permission from American Thoracic Society. [Am J Respir Crit Care Med] (Kinnula V.L. et Al., Oxidative 
stress in pulmonary fibrosis, 2005. 172(4): p. 417-422) Copyright 2005 
 
Anti-oxidants are the main line of defense against oxidative damage in the lung. 
Exogenous and endogenous irritants in IPF create a redox imbalance, resulting in 
the production of ROS, which potentiate pulmonary fibrosis. Shown are 
endogenous antioxidants and the steps at which they can protect the lung from the 
effects of ROS. a1PI = a1-proteinase inhibitor; a2M = a2-macroglobulin; 
CuZnSOD = SOD1; ECSOD = SOD3; eGPx = extracellular glutathione peroxidase; 
GPx = glutathione peroxidase; HO-1 = heme-oxygenase 1; MnSOD = SOD2; TIMP = tissue inhibitor of metalloproteinases.  
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1.14 Modeling Pulmonary Fibrosis 
 
IPF occurs without cause in the majority of patients, making it difficult for 
science to develop relevant animal models that resemble human disease. Several 
models have been used to study pulmonary fibrosis, yet none can accurately 
recapitulate IPF. Fibrosing lung disease occurs naturally in a variety of animals 
including horses, cats, donkeys, and dogs (e.g. Westie Terriers) [154-158]. 
Although these are considered to have pulmonary fibrosis, the similarities between 
animal and human disease still need to be elucidated and, thus, they are difficult 
to use for research due to a myriad of issues including physiological differences, 
genetics, prevalence and cost [159]. 
More commonly, inducible models of pulmonary fibrosis are utilized. 
Bleomycin-induced pulmonary fibrosis is the most commonly used model to 
investigate the mechanisms that lead to tissue remodeling after lung injury [160]. 
Bleomycin has been used as an anti-cancer agent, as it is a glycopeptide 
antineoplastic agent derived from Cu(II)complexes from bacterium Streptomyces 
verticillus. Bleomycin is effective towards reducing or inhibiting the growth of 
neoplasias by degrading cellular DNA with single- and double-strand breaks. This 
is due to a DNA-binding and iron-binding site. Bleomycin forms a complex with 
iron, causing the iron to oxidize, therefore, reducing oxygen into free-radicals. The 
free-radicals cause single- and double-strand DNA breaks, leading to apoptosis, 
which is useful in causing damage to cancer cells. An unwanted side effect of 
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bleomycin treatment, however, is the development of pulmonary fibrosis due to low 
abundance of the inactivating enzyme, bleomycin hydrolase, in the lung [161-163].  
Physiologically, intratracheal bleomycin instillation elicits an acute 
pneumonitis characterized by the infiltration of the lung with immune cells within 
the first week. After the second week, inflammation subsides and the fibrotic stage 
of lung injury begins to form with the activation of tissue remodeling genes 
including fibronectin, collagens and TGF-b [164-166]. This phase is characterized 
by modification of the original lung architecture and formation of pulmonary fibrosis 
(Figure 7). 
Today, bleomycin is considered one of the best animal models to studying 
lung fibrosis due to several similarities with the human disease. IPF and bleomycin-
induced lung fibrosis share activation of (M2) macrophages, EMT, and micro-
MRNA 21 induction [167-170]. One of the main drawbacks of the bleomycin model 
is the changing conditions between the different stages and the fact that the 
fibrosis is reversible [171]. Additionally, there is absence of hyperplastic type II 
AECs [172].  
The bleomycin model has provided some insight into the role of tobacco 
exposure in pulmonary fibrosis, with cigarette smoke exposure enhancing alveolar 
architecture derangements in hamsters and guinea pigs [173-175].  However, 
cigarette exposure failed to enhance bleomycin-induced lung fibrosis in rats, but 
the exposure was not initiated till post bleomycin [176]. Thus, there appears to be 




Figure 7. Bleomycin-Induced Model of Pulmonary Fibrosis 
Vicary, Unpublished. 
 
Bleomycin elicits an acute pneumonitis characterized by early infiltration of the lung 
with immune cells within the first week. In addition to inflammation, there is 
activation of tissue remodeling genes including fibronectin, collagens, and pro-
fibrotic TGF-β. Two weeks after bleomycin instillation, inflammation subsides and 
a fibrotic stage of lung injury begins to form after the second week. This phase is 
characterized by modification of the original lung architecture and replacement with 













The lung is one of the few organs constantly expanding and contracting. 
How pulmonary fibrosis affects the mechanobiology of the lung and vice versa has 
only recently been investigated. Tissue forces were proposed to regulate tissue 
remodeling over a century ago, but it has taken modern research technology to 
begin to explore the relationship between mechanical forces and cellular behavior. 
Recent research has demonstrated that most eukaryotic cells can interact with the 
ECM and generate intracellular forces that affect cellular stiffness [177], 
cytoskeletal dynamics [178], cell migration [179-181], differentiation [182, 183] and 
drug response [184]. Cells can sense changes in the tensile strength and elastic 
recoil of the lung, which is determined by fibrillary proteins, such as collagens and 
fibronectins [185, 186].  
During homeostasis, the turnover of ECM proteins varies greatly, which can 
alter the ECM stiffness [187]. Collagen fibers are estimated to remodel at 3-10% 
per day, whereas elastin fibers, another ECM protein, are life-long, surviving 
approximately 74 years [188, 189]. Disorders of matrix remodeling share a 
common paradigm with disease progression: provisional matrices formed in the 
context of injury emit signals to promote inflammatory responses and activate 
epithelial cells, provoking the production of connective tissue elements that lead to 
persistent and at times permanent matrix remodeling [190]. These changes in the 
rate of tissue remodeling likely plays an important role in pulmonary disease 
progression.  
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Increased collagen deposition in IPF is associated with marked increases 
in lung stiffness, which has been shown to alter fibroblast morphology, 
proliferation, TGF-b signaling, and myofibroblast activation [59, 191-194]. Collagen 
fibers affect matrix stiffness by strengthening protein–protein interactions and 
other physical characteristics such as resistance to proteolysis, emergence of 
neoepitopes, and enhanced cell–matrix interactions [195]. Collagen crosslinking 
can also play a major role in determining matrix stiffness, which feedbacks to 
increase additional collagen deposition in fibroblasts [196]. Enzymes can affect 
crosslinking, such as the lysyl oxidase family [195]. These various post-
translational modifications can result in significant changes of ECM moduli (protein 
ratios) and resultant pathology when normal remodeling functions are modified.  
Traditionally, in vitro studies of cell-matrix interactions have used matrix-
coated culture dishes of either solidary proteins such as collagen, or mixtures like 
MatrigelÒ. These conditions do not recapitulate the in vivo 3D environment, 
however, as they lack characteristics such as the heterogeneity of lung tissue or 
3D orientation of proteins. In vivo, cells protrude in all directions, often coming into 
contact with several ECM proteins at once. This is a limitation of culture systems, 
where cells react differently than cells in 3D environments [197-200]. Additionally, 
in vivo, cells are exposed to different ECM stress and strain forces due to the lung 
continuously expanding and contracting, exposing pulmonary cells (endothelial, 
epithelial and fibroblasts) to rhythmic stress and strain, which are necessary for 
cellular homeostasis. For example, airway epithelium exposed to cyclic stretching 
increases the production of surfactant and barrier function [201].  
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To study these 3D microenvironments in a more relevant system, the 
process of organ decellularization was developed, removing all cellular material, 
while retaining the ECM in its native 3D structure. Several processes have been 
published with variability in loss of proteins, growth factors, and matrix-associated 
molecules, depending on detergents uses, pressure applied, and the length of the 
process [202-204]. Decellularization allows measurement of the mechanical 
characteristics of the ECM with the development of physical tools such as the 
atomic force microscope (AFM) [205]. AFM is a high-resolution microscopy that 
uses a probe to touch the tissue surface and detect characteristics (force, imaging, 
sample manipulation) in the nanometer range (Figure 8) [206]. These strain/stress 
forces are expressed as elastic (Young’s) modulus, which describes the force 
necessary to deform materials [207]. Different organs and tissues have different 
Young’s modulus (Pa) based of cell types and composition of ECM, among other 
factors, ranging from 50 Pa (blood plasma) to bone (100,000 Pa) (Figure 9) [208]. 
This is very different from tissue culture dishes which have Young’s moduli of 2-
4GPa [208]. Booth et. al. showed that after removal of cells, the normal human 
lung elastic modulus is 0.44 to 7.5 kPa [59]. Several pulmonary diseases are 
associated with changes in lung Young’s modulus, including emphysema having 
decreased stiffness, and fibrotic disorders such as IPF, having increased lung 







Affecting over 100,000 Americans and carrying a dismal diagnosis, IPF is a 
horrible disease. Diagnostic techniques have improved, but understanding the 
cause of IPF is still convoluted. This dissertation investigates the potential role of 
a transition matrix induced by nicotine exposure, and its effect on IPF formation 
and death associated with exposure to lung injury. Additionally, tracking of IPF is 
crucial to patient treatment, to which I investigate inclusion of obstructive airway 
measurement to improve IPF progression using spirometry values. Improving our 
understanding of the mechanisms by which tobacco promotes lung remodeling, 
will lead to the development of better tools for diagnostic tracking, care and 





Figure 8. Mechanisms of Atomic Force Microscopy 
  




Atomic force microscopy is a high-resolution microscope that uses a probe to touch 
the tissue surface and detect characteristics (force, imaging, sample manipulation) 
in the nanometer range using laser defection off a cantilever. These strain/stress 
forces are expressed as elastic (Young’s) modulus, which describes the force 




Figure 9. Lung Mechanobiology 
 
Reprinted with permission from Nature Publishing Company. [Nature Review Cancer] (Butcher, D.T. et Al., A tense 
situation: forcing tumour progression, 2009. 9(2): p. 108-122) Copyright 2009 
 
Substrate stiffness has been shown to alter fibroblast morphology, proliferation, 
TGF-b signaling, and differentiation. Organs and tissues have different Young’s 
modulus (Pa) based of cells types, composition of ECM, among others ranging 
from 50 Pa (blood plasma) to bone (100,000 Pa). This is very different from tissue 





MATERIAL AND METHODS 
 
2.1 - Overview 
 
 This dissertation consists of in vivo and in vitro experiments capable of 
investigating the complex interplay of nicotine and fibroblasts with the extracellular 
matrix. My experimental designs shed light on the potential role of nicotine and the 
a7 nAChR in the pathogenesis of pulmonary fibrosis.  
 
2.2 - Reagents 
 
The mitogen-enhanced kinase-1 (MEK-1) inhibitor PD98059 was purchased 
from New England Biolabs, Inc. (Beverly, MA) and the a7 antagonist, MG-264, was 
purchased from Santa Cruz (Dallas, TX). Trypsin 10x was purchased from Corning 
Cellgro (Manassas, VA) and diluted to 2.5X with dH20. Mouse a7 nAChR siRNA, 
and control non-target siRNAs and Real-Time Quantitative PCR primers (QuantiTect 
Primer Assays, Qiagen, Valencia, CA) used to quantify mRNA levels by Real-Time 
RT-PCR were purchased from Qiagen. 
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 All other reagents were purchased from Sigma Chemical Company (St. Louis, MO) 
or Fisher Scientific (Pittsburgh, PA) unless otherwise specified. 
 
2.3 - Cell Culture 
 
Murine NIH3T3 fibroblast from the American-Type Culture Collection (CRL 
#1658; Manassas, VA) and primary lung fibroblasts (between 3-10 passages) were 
harvested from wildtype control C57BL/6 or a7 nAChR deficient C57BL/6 mice 
(Jackson Laboratories, Bay Harbor, MA) and cultured in Dulbecco's Modified 
Eagle Medium (DMEM; Corning Cellgro), as previously described [77, 211]. The 
lack of a7 nAChRs in knock-out mice was verified by RT-PCR and Western Blot 
(Figure 12). U937, human monocytic cells permanently transfected with human IL-
1b gene promoter connected to a luciferase reporter gene were cultured in 
400ug/ml HyClone geneticin G418 (Thermo Scientific, Waltham, MA) in RPMI-
1640 (Corning Cellgro). THP-1 monocytic cells transiently transfected with the 
luciferase gene connected to matrix metallopeptidase 9 (MMP-9) promoter were 
cultured in RPMI-1640 [212]. All media was supplemented with 10% fetal bovine 
serum (Atlanta Biologicals, Lawrenceburg, GA) and 1% Antibiotic Antimitotic 
Solution (Corning Cellgro). Cells were grown in Heracell 150 incubators (Thermo 




2.4 - Isolation and Detection of mRNAs by Reverse-Transcriptase 
Polymerase Chain Reaction 
 
RNA isolation and real-time PCR were performed in two ways. First was 
cells were lifted from wells with cell scrapers (Corning) and centrifuged (550 x g 
for 5 minutes). PBS were aspirated then 400-500 µL of RNAzol B™ (Tel-test Inc., 
Friendswood, TX) was added to the harvested cells and vortexed. Chloroform-
isoamyl alcohol (400 µL) was added, vortexed, and placed on ice for 15 minutes. 
Samples were spun at 4oC for 15 minutes at 17,500 x g. mRNA was transferred to 
a new microfuge tube and 500 µL cold isopropanol were added, mixed, and 
incubated on ice for 15-30 minutes. Samples were spun at 4oC for 15 minutes at 
17,500 x g, and pellet washed with 95% EtOH and then 70% EtOH. mRNA pellets 
were resuspended in 100 µL of RNAse free H2O with 1 mM EDTA. mRNA 
concentrations were determined by OD260 x dilution factor x 40 = ng/µl in crystal 
cuvettes using a GS-800 Calibrated Densitometer (Bio-rad). Reverse transcription 
was performed using iScriptÔ cDNA Synthesis Kit (Bio-rad) according to 
manufacturer’s protocol. 
PCR was performed using iTaqÔ Universal SYBRâ Green Supermix (Bio-
rad) [211]. Primer sequences are as follows: Mouse collagen type I forward (5’-
GTGCTGTTGGTGCTGCTG), reverse (5’-CAGGAGCACCAGCAATAC); 18S 
forward (5’-GTGACCAGAGCGAAAGCA), reverse (5’-
ACCCACGGAATCGAGAAA); Mouse fibronectin forward primer 
(CTGTGACAACTGCCGTAG), reverse primer (CAGCTTCTCCAAGCATCG), 
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probe (ACCAAGGTCAATCCACA C); IL-1b forward (5’-
GAGCACCTTCTTTTCC), reverse (5’-CTGGTGGAAGAAAAGG), probe; mouse 
a-SMA forward primer (7ATGGAGTCAGCGGGCATC), reverse primer 
(AACTGGAGGCGCTGATCC), probe (AGCCACCGATCCAGACAG); mouse β-
actin forward primer (ATGGATGACGATATCGCT), reverse primer (ATGAGGT 
AGTCTGTCAGGT), probe (GGATGGCTACGTACATGGCT); and a7 nAChR 
forward (5’-CTGCTGGGAAATCCTAGGCACACTTGAG or 
GACAAGACCGGCTTCCATCC), reverse (5’-
CCTGGTCCTGCTGTGTTAAACTGCTTC) in a Labnet Multigene Gradient 
thermocycler (Edison, NJ) for PCR and Cepheid SmartCycler (Cepheid, 
Sunnydale, CA) for real-time PCR. Negative controls consisted of dH2O and 
mRNA without PCR agents. Values were normalized to 18S or GAPDH and 
expressed as relative change vs. untreated mouse lung tissue. 
 The second method of isolation and detection isolated mRNA with Quick-
mRNAÔ Micro- or Mini-Prep kits (Zymo Research, Irvine, CA) according to 
manufacturer’s protocol. Real-time PCR conducted using Fast SYBR Master Mix 
(Applied Biosystems, Foster City, CA) using certified mouse primers for 18S 
(Mm03928990_g1), b-Actin (Mm04394036_g1), GAPDH (Mm99999915_g1), 
Collagen Type 1 (Mm00801366_g1), Fibronectin (Mm01256744_m1), IL-
1b (Mm00434228_m1) SOD1 (Mm01344233_g1), TGF-b1 (Mm01178820_m1), 
TNF-a (Mm00443258_m1) (Life Technologies, Carlsbad, CA) in a StepOnePlusÔ 
real-time PCR system (Life Technologies). Negative controls consisted of dH2O 
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and mRNA without PCR agents. Values were normalized to 18S, b-Actin, or 
GAPDH and expressed as relative change vs. untreated samples. 
 
2.5 - Protein Detection via Western Blotting 
 
Western blots were performed as previously described [77, 211]. Samples 
were isolated using western homogenization buffer (50 mM NaCl, 50 mM NaF, 50 
mM NaP2O7-10 H2O, 5 mM EDTA, 5 mM EGTA, 2 mM Na3VO4, 0.5 mM PMSF, 
0.01% Triton X-100, 10 µg/ml leupeptin, 10 mM HEPES, pH 7.4), and sonicated 
for 5 seconds using Sonifier 450 (Branson, Danbury, CT). Protein concentrations 
were determined using Bradford reagent (Sigma) readings in DU-800 
Spectrophotometer (Beckman Coulter, Brea, CA). Gels were either 10% 
(denaturing) or 8% (native) acrylamide gels (Bio-rad, Hercules, CA) run in a mini 
trans-blot system (Bio-rad). Samples were heated to 95oC for 5 minutes and spun 
for 10 minutes at 17,500 x g. Gels were run for 2 hours at 125 volts using a 
Powerpack HC power supply (Bio-rad).  
Protein was transferred to Protran Nitrocellulose transfer membrane 
(Whatman), between 4 pieces of extra thick western blotting filter paper (Thermo 
Scientific), soaked in Pierce Western Blot Transfer Buffer (Thermo Scientific), then 
transferred for 2 hours at 25 volts in Trans-Blot SD semi-dry transfer cell (Bio-rad). 
Membranes were agitated in wash buffer (3 x 10 minutes) and then incubated in 
5% Bovine Serum Albumin or 5% non-dry fat milk blocking buffer for 1 hour. Blots 
were incubated with primary polyclonal antibody against either GAPDH (Sigma; 
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1:1000 dilution), Collagen type I (Abcam, Cambridge, MA; 1:10000; native, non-
reducing gel), p-Smad3 (Rockland Immunochemicals, Gilbertsville, PA; 1:2000), 
p-Erk 1&2 (Cell Signaling, Beverly, MA; 1:1000), total Smad3 (Upstate Cell 
Signaling, Lake Placid, NY; 1:1000), total Erk (Cell Signaling; 1:1000), and a7 
nAChR (Sigma; 1:500) overnight at 4oC. Membranes were agitated in wash buffer 
(3 x 10 minutes) before incubation in 2o antibody goat anti-rabbit IgG (Sigma; 
1:20,000) for 1 hour at room temperature.  
Non-florescent blots were incubated with Amersham ECL Western Blotting 
Detection Reagents (GE Healthcare, Little Chalfont, UK) for 5 minutes and 
exposed to Genemate Blue Basic Autorad film (Bioexpress, Kaysville, UT) for up 
to 1 hour. Protein densitometry was completed using GS-800 Calibrated 
Densitometer (Bio-rad). 
Florescent lots were incubated with secondary goat anti-rabbit IgG (HRP-
conjugated) (Li-CORE, Lincoln, NE) (1:20000). Membranes were agitated in wash 
buffer (3 x 10 minutes). Florescent blots read on a LI-COR Odyssey CLx imaging 
system and analyzed in Image Studio (LI-COR).  
 
2.6 - Cell Viability (Proliferation) Assay   
 
Wildtype or transfected primary lung fibroblasts (1 x 104 cells/ml) were 
added to 96-well tissue culture plates and incubated at 37oC for 24 hours in 
COMPLETE™ Serum-Free/Low-Protein Medium (Corning Cellgro), then for up to 
72 hours with nicotine (50 µg/ml) in the presence or absence of the MEK1 inhibitor, 
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PD98059 (50 µM). Afterwards, the luminescence of viable cells was detected using 
Cell Titer-Glo Luminescent Cell Viability Assay Kit (Promega) in a Luminoskan 
Ascent Luminometer (Beckman Coulter) according to the manufacturer’s 
instructions.  
 
2.7 - Matrix Deposition and IL-1b Measurement 
 
Fibroblasts were cultured for 24 hours then treated with nicotine (50 μg/ml), 
PD98059 (50 µM), and/or MG-264 (10 µM) in DMEM (Cellgro) and retained in 
culture in 6 well Costar Cell Culture plates (Corning) for 120 hours. Afterwards, the 
fibroblasts were eliminated by osmotic lysis and the remaining matrix-coated 
dishes were washed thoroughly [213]. Cells were washed once with PBS 
containing 1 mM EDTA (Solution A), then treated for 30 minutes at 4°C with the 
solution B (0.25 M NH4OH, 1 mM EDTA, 1 mM PMSF). The cells were washed 2 
additional times with solution 3A, and then treated for 15 minutes at 4°C with 
solution C (1 M NaCl in 50 mM Tris (pH 7.4), 1 mM EDTA, 1 mM PMSF). Lastly, 
the culture plates were washed once with solution A. Isolated matrices were stored 
at 4°C with PBS. 
Human monocytic U937 cells permanently transfected with the human IL-
1b gene promoter fused to a luciferase reporter gene were incubated in RPMI-
1640 on matrix-coated plates for 24 hours [214]. Inhibition was achieved by pre-
treatment of mouse IgG (1:100, Sigma) or anti-a2b1 integrin (1:100, Abcam) 
antibody for 1 hour followed by culturing with the matrix-coated plates 24 hours. 
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Afterwards, the luminescence of viable cells was detected using Cell Titer-Glo 
Luminescent Cell Viability Assay Kit (Promega). 
 
2.8 - Superoxide Dismutase Activity Assay  
 
Activity of superoxide dismutases was determined using an in vitro assay 
as previously published [215]. The quantity of SOD required to produce 50% 
inhibition of the rate of reduction of cytochrome c under specified conditions is 
defined as 1 unit. Samples were collected in 600 µL cold PPS solution (50 mM 
potassium phosphate, 0.1 mM EDTA, H20, pH 7.8) and homogenized thoroughly 
and spun for 30 minutes at 14,000 x g. In a GS-800 Beckman Coulter 
spectrometer, the control reaction was determined adding Ferricytochrome C 
(Cytochrome C) 0.1mM (Sigma #C7752), Xanthine (Sigma #X4002), and 
Phosphate buffer (800 µL) into 1 mL plastic cuvette with light path 1 cm at 25°C. 
Reaction initiated by adding 10 µL Xanthine Oxidase (Sigma #X4875) and the 
sample and read at 550 nm every 30 seconds for 300 Seconds.  
 
2.9 – Murine Housing 
 
Wildtype or a7 nAChR deficient C57BL/6 mice (female, 8-12 weeks; 
Jackson Laboratories) were housed on a 12-hour light cycle in a pathogen-free 
barrier facility accredited by the Association for Assessment and Accreditation of 
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Laboratory Animal Care. The University of Louisville’s Institutional Animal Care 
and Use Committee approved all animal studies. 
 
2.10 – Murine Nicotine Exposure 
 
Wildtype and a7 nAChR knockout C57BL/6 mice (female, 8-12 weeks) were 
fed a normal diet and exposed to nicotine in their drinking water (100 µg/ml) for 8 
weeks as previously described by Rowell et al. [216, 217].  Per Rowell’s research, 
mice received an average of 28.6 mg/kg of nicotine a day with a plasma nicotine 
concentration approximately 40 ng/ml (0.21 µM), which is comparable to what has 
been seen in humans. In vitro doses of nicotine (1-100 µg/ml) used was chosen 
based on previous experiments in the lab and published literature [77].  
 
2.11 – Murine Cigarette Smoke Exposure 
 
In collaboration with Douglas Arenberg at the University of Michigan, mice 
were exposed to cigarette smoke with an automated smoking machine (Jaeger-
Baumgartner CSM) as previously described [218-220]. The machine draws a puff 
of smoke in two seconds at a flow of 1.02 liters/min, once each minute. The smoke 
was diluted with medial grade air at 3 liters/min and injected into a sealed 22-gallon 
fish tank containing up to 5 Mico-isolator mouse cages (tops removed). This 
mixture yields a particulate content of 250 mg/cubic meter. Mice were exposed 4 
hours/day 5 days/week for up to 6 months. Exposures are well tolerated using this 
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system for up to one year with acceptable levels of carboxyhemoglobin.  
 
2.12 – Murine Bleomycin-Induced Injury 
 
Bleomycin-induced lung injury was performed as previously described [70]. 
Mice received either bleomycin (1.0 or 2.0 U/kg) (Sigma) in phosphate-buffered 
saline (PBS) or vehicle (PBS) alone intratracheally. Mice were euthanized at 12 or 
21 days following injury. Mice were euthanized followed by mRNA and protein 
isolation along with en bloc isolation of the lungs for analysis.   
 
2.13 – Murine Bronchoalveolar Lavage (BAL) 
 
Bronchoalveolar lavage (BAL) was performed as previously described 
[212]. Cells obtained from BAL were plated for 1 hour at 37°C and the supernatant 
collected. Supernatant (100 µL) was cultured on NIH3T3 fibroblasts or THP-1 
monocytes for 24 hours. The supernatants from culture were utilized in fibronectin 
or MMP-9 gene transcription assays using Luciferase Assay Reagent (Promega) 
as previously described [212]. 
 
2.14 – Murine Histological Analysis 
 
Mice were euthanized by exsanguination followed by en bloc isolation of the 
lungs which were inflated at standard pressure, fixed in formalin, paraffin-
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embedded, and sectioned (5 µm) using JUNG RM2055 microtome (Leica, Buffalo 
Groce, IL), then transferred onto Colorfrost microslides (VWR Sciences, Radnor, 
PA) for histological analysis. Lung sections were stained using Weigert's iron 
hematoxylin for 10 minutes, rinsed in dH20, then treated with Biebrich scarlet-acid 
fuchsin solution for 10 minutes. The slides were washed in dH20, then transferred 
to aniline blue stain for 30-60 minutes (Masson Tri-chrome Staining Kit, Richard-
Allan Scientific, Kalamazoo, MI). For Sirius Red/Fast Green staining, slides were 
treated with 5% Sirius Red (Polysciences Inc, Warrington, PA) and then were Fast 
Green (Achros, New Jersey) saturated with picric acid for 30 minutes each. Lung 
microscopy pictures were taken with XL Core EVOS microscope (Life 
Technologies, Carlsbad, CA). The tri-chrome slides were blindly graded on their 
intensity of collagen staining by 6 investigators based on the Ashcroft score as 
previously described [221]. 
 
2.15 - Protein Detection via Immunohistochemistry 
 
Immunohistochemistry was performed as previously described [77, 222]. 
Application of primary antibodies against fibronectin, DAPI, IgG, or IL-1b (Abcam, 
1:100 dilution) were incubated at 4 °C overnight. HRP-conjugated secondary 
antibodies were applied (Sigma), and the specific staining was visualized with 
Vectastain ABC Kit (Vector Labs, Burlingame, CA). Lungs of smoked and nicotine-
treated mine were processed and incubated with fibronectin antibodies Afterwards, 
the tissue sections were de-identified and the sections were scored for fibronectin 
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expression by two investigators blinded to treatment groups. 
 
2.16 – Murine Lung Decellularization 
 
Based off previously published method [59], mice were euthanized by CO2. 
Lung and heart were isolated en bloc. All reagents were made fresh for each use. 
Lungs were perfused in a 50 mm cell culture dish by injecting 10 cc of DI solution 
(dH20 with 1% Antibiotic Antimitotic Solution (Corning Cellgro)) into the right 
ventricle of the heart. Three-cc syringe with 19-gauge needle were filled with DI 
solution and inserted into trachea and secured with 2 silk suture knots. Lungs were 
inflated with DI solution with needle left in trachea. All perfusion steps were 
performed by injecting 3 mL intracardiac and intratracheal samples of each of the 
solutions and the lungs were allowed to recoil and expel any excess fluid. 
Perfusions consisted of 0.1% Trition X-100 (Sigma), 2% Na deoxycholate (Fisher), 
1M NaCl (Fisher), and DNAse solution (DNAse I (Sigma), 30 µg/ml in 1.3 mM 
MgSO4 and 2 mM CaCl). Perfusions of each solution were followed by incubations 
at 4oC on a rocker with gentle stirring for minimum of 1 hour each, and solution 
change were performed in the tissue culture hood. After each incubation, the lungs 
were flushed with DI solution before the next perfusion. Once the decellularization 
process was complete, the lungs were stored in 50 mL conicals containing PBS 
with 100 µg/ml Antibiotic Antimitotic Solution (Corning Cellgro) and 2.5 µg/ml 
Amphotericin B (Lonza) until embedding. 
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Lungs are embedded in 6% Seaprep Ultra Low Agarose (LONZA). Agarose 
was prepared on hot plate with stir rod and allowed to mix at medium heat until 
fully dissolved. Once melted, agarose was placed in a 55 °C degree water bath 
until use. Lung was dried on paper towel and dabbed dry. One and half mL 6% 
ultra-low melt agarose was injected into the trachea and heart and the organs were 
cut out and the lung dissected into separated lobes, placed into embedding molds, 
and covered with additional agarose. The embedded tissue was stored in a sealed 
container with a humidification agent. 
Lung sections cut on Vibratome (Leica VT 1200, Wetzlar, Germany) at 0.2 
mm/s and 500 nm. Loctite (Office Max, Cat# A11363588) was used to glue sample 
to cutting platform. Cut samples were stored in DI solution in 50 mL conical. The 
agarose was melted by adding the tubes into a water bath set to 50˚C. To sterilize 
the slices before use, the DI solution was changed to MQ water plus 0.18% 
peracetic acid (Pfalz & Bauer) plus 4.8% EtOH over night or the weekend at 4˚C. 
Afterwards, the sterilizing solution was decanted and cold sterile filtered water was 
added and rocked in cold room.  
 
2.17 - Atomic Force Microscopy 
 
Matrix stiffness was measured by atomic force microscopy (AFM). Stress is 
the magnitude and direction of the force on the cell and strain is the magnitude 
and direction of distortion (force/area) [223]. AFM is a very high-resolution type of 
scanning probe microscopy that utilizes a cantilever as a probe to characterize the 
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surface of a sample. When the tip of the cantilever contacts the sample, forces 
between the tip and the sample lead to a deflection of the cantilever. The deflection 
is measured based on the displacement of a laser using an array of photodiodes. 
Based on a previously published method [165]. Samples were tested with 
MFP-3D-Bio AFM Microscope (Asylum Research, Santa Barbra, CA) using 
cantilevers with a 0.03 N/m spring and 10 µm SiO2 Sphere tip (Novascan, Ames, 
IA). A force map (80 µM scan size) was generated with a 16 x 16 spot test pattern 
for a total of 256 points. Each force plot was conducted with a velocity of 2 µM/s 
and a trigger point of 500 nM. Young’s modulus was determined using a Hertz fit 
model, setting the tip poisson of 0.19 and modulus of 68 GPa, and a sample 
poisson of 0.4. The upper limit of the calculation region was set at 75% of the 
curve. Data gathered and analyzed using Asylum Modified (Version 14) Igor Pro 
software (6.22A WaveMetrics Inc., Portland, OR). 
 
2.18 - Statistical Evaluation 
 
All experiments were repeated using at least 3 samples. Means plus 
standard deviations of the means were calculated for all experimental values. 
Significance was assessed by p-values <0.05, which were obtained using two-
tailed t-tests in Microsoft Excel (Redman, WA) or 2-way ANOVA with Bonferroni 
posttest in Graphpad Prism 6 (Graphpad Software, La Jolla, CA).  
 
2.19 - PANTHER Trial Data 
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 The datasets for the Prednisone, Azathioprine, N-acetyl cysteine in IPF 
(PANTHER) Trial were obtained from NIH-NHLBI-sponsored Biologic Specimen 
and Data Repository Information Coordinating Center (BioLincc). This study was 
designed and conducted by the Idiopathic Pulmonary Fibrosis Clinical Research 
Network (IPFnet). The trial lasted 60 weeks and participants received a 
combination of prednisone, azathioprine, and NAC (combination therapy), NAC 
alone, or placebo in a 1:1:1 ratio [224] (ClinicalTrials.gov number, NCT00650091). 
At the end of the trial, increased risks of death and hospitalization were observed 
in patients treated with a combination of prednisone, azathioprine, and NAC, but 
no difference in FVC was detected. The database provided 240 patients for 
analysis. Because no difference in FVC was detected between treatment and 
placebo groups in the trial, all 85 patients (43 placebo/42 treatment) who achieved 
>10% decline in the FVC during the study were included in statistical analysis. 
Spirometry values were collected every 15 weeks during the trial period of 60 
weeks. Secondary outcomes include the frequency of re-hospitalizations and time 
of death. 
 
2.20 - PANTHER Trial Statistical Analysis 
 
 The analysis was completed in R (Version 3.2.4) [225]. A 10% loss in either 
FVC or FEV1/dFVC determined by comparing the baseline to the maximum 
reading from the 15, 30, 45, or 60-week follow-up. Descriptive statistics were ran 
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comparing placebo and treatment groups. Chi-squared or Fisher’s exact tests were 
used as appropriate to test for differences between categorical variables. Wilcoxon 
rank sum tests were used to test for differences in continuous variables. The Stuart 
Maxwell Marginal Homogeneity Test (an extension of McNemar’s test) was used 
to assess differences timing of loss between FVC and FEV1/dFVC. Receiver 
operating characteristics (ROC) curves were produced to compare the FEV1/dFVC 
ratio versus FVC alone in regards to sensitivity and specificity as a predictor of 
death and re-hospitalization.   
 
2.21 - PANTHER Trial Human Subject Protection 
 
This study was approved by the University of Louisville Institutional Review 






THE EFFECTS OF NICOTINE ON LUNG FIBROBLAST PROLIFERATION AND 
COLLAGEN EXPRESSION/DEPOSTION IN VITRO AND IN VIVO, AND THE 




Tobacco is considered the single greatest cause of preventable death in the 
world [226]. Chronic tobacco exposure is associated with the development of 
chronic lung disorders like chronic obstructive pulmonary disease and idiopathic 
pulmonary fibrosis (IPF), and is the main cause of lung cancer globally [226]. 
Tobacco smoke contains more than 4000 chemicals, which interact with a 
multitude of molecules and pathways, preventing the effective and safe targeting 
of a single mechanism of action with significant therapeutic benefit. A larger effect 
of tobacco smoke inhalation is the induction of inflammation, a process 
characterized by the release of soluble mediators, oxidant stress, and the 
recruitment of inflammatory cells into tissue [227]. This promotes tissue 
remodeling, including alterations in lung structure and function, and oncogenesis 
[228].
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Due to nicotine’s well known addictive effects, attention has turned to this 
plant derived alkaloid which represents ~0.6–3.0% of the dry weight of tobacco. 
Recent studies have unveiled the effects of nicotine on lung development [34, 35] 
and on inflammatory processes [229].  This is possible because of the existence 
of nicotinic receptors in lung tissue capable of signal transduction [79]. These 
receptors, termed nicotinic acetylcholine receptors (nAChRs), are multimeric 
acetylcholine-triggered channel proteins that form homomeric and heteromeric a 
and b chain pentameters. The a7 nAChR is the most abundant homomeric 
receptor form, composed of five a7 subunits. In developing primate lungs, a7 
nAChRs were detected in airway epithelial cells, around large airways and blood 
vessels, free alveolar macrophages, alveolar type II cells, and pulmonary 
neuroendorcrine cells [34]. Additionally, increased a7 nAChR expression has been 
shown with nicotine administration in bronchial epithelial and endothelial cells as 
well being implicated in regulation of inflammation and cancer [77, 92-94].  
Our laboratory has previously demonstrated that nicotine stimulates lung 
fibroblasts to express fibronectin through induction of the MEK-1/Erk pathway [77]. 
Fibronectin is a matrix glycoprotein, which is highly expressed in injured tissues, 
and is considered a sensitive marker of tissue injury and activation of tissue 
remodeling [60, 61]. In an injured lung, fibronectin is deposited over denuded 
basement membranes where it is thought to support the migration of alveolar 
epithelial cells during repair [61]. The excessive deposition of fibronectin, however, 
has been hypothesized to promote disrepair [70]. Human studies also show 
increased fibronectin content in the bronchoalveolar lavage fluid of smokers [75]. 
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However, nicotine-induced fibronectin expression and deposition are not sufficient 
to alter overall lung architecture and to date there are no data suggesting that 
nicotine, alone, promotes significant lung tissue remodeling. 
In this study, nicotine is shown to stimulate lung fibroblasts to express 
collagen type I. This fibrillar collagen is another extracellular matrix component 
highly expressed in tissues during injury and repair, and its expression signals 
activation of tissue remodeling. Collagen type I is the most abundant form of 
collagen in the human body and is present in connective tissue throughout the 
body including tendon, ligament, skin, and lung tissue. Each rope-like procollagen 
molecule is made up of three chains: two pro-a1 (I) chains, which are produced 
from the COL1A1 gene, and one pro-a2 (I) chain, which are produced from the 
COL1A2 gene. After processing, the resulting mature collagen molecules arrange 
themselves into long, thin fibrils. Individual collagen molecules are then cross-
linked to one another within these fibrils thereby forming strong collagen fibrils. 
Studies performed in vivo confirmed nicotine induction of collagen type I without 
changes in overall lung architecture in lung matrix. Also, we found that nicotine-
treated fibroblasts produce a collagen-containing matrix capable of stimulating 
monocytic cells to produce the pro-inflammatory cytokine IL-1b in vitro. 
Together, these observations suggest that nicotine stimulates alterations in 
the relative composition of the lung extracellular matrix favoring fibronectin [77] 
and collagen type I (this report) expression without altering the overall tissue 
architecture of the lung. These subtle changes may render the host susceptible to 




Nicotine stimulates the expression of collagen type I  
 While exploring the effects of nicotine on lung cells, we found that nicotine 
stimulated the expression of collagen type I in lung fibroblasts. As depicted in 
Figure 10, nicotine induced the expression of collagen type I mRNA in a dose-
dependent fashion (Figure 10). Maximum mRNA expression was observed at 50 
μg/ml of nicotine. Twenty-four hours after nicotine stimulation, increased collagen 
type I protein was detected in cell extracts (Figure 10). Nicotine also stimulated 
collagen type I mRNA and protein expression up to 72 h (Figure 11). 
 
Role of a7 nAChRs in collagen expression and cellular proliferation 
 We evaluated the expression of a7 nAChR in a7KO and wildtype mice 
(Figure 12). RT-PCR verified the absence of a7 nAChRs in the a7KO mice. We 
then evaluated nicotine-induced collagen type I mRNA expression in primary lung 
fibroblasts harvested from a7KO animals. Nicotine failed to stimulate collagen type 
I expression in a7KO cells (Figure 12). Similarly, we found nicotine did not induced 
collagen type I protein expression in a7KO fibroblasts. (Figure 12). Nicotine also 
stimulated the proliferation of lung fibroblasts and this effect was also through a7 
nAChRs. As depicted in Figure 13, nicotine-induced proliferation was inhibited at 
48 and 72 h by siRNA silencing of a7 nAChRs. Additionally, the mitogenic effects 
of nicotine were inhibited by PD98059, a MEK-1/ERK inhibitor (Figure 14).  
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Figure 10. Nicotine Stimulates Collagen Type I mRNA and Protein 
Expression 
Vicary et. Al. 2016 
 
 (A) Primary lung fibroblasts (1 x 106 cells/6 well) were treated with nicotine (1-75 
μg/ml) for 24 hours. Real-time PCR reactions were performed using mouse 
collagen type I or 18S primers. Note that nicotine induced a dose-dependent 
increase in collagen type I mRNA expression. mRNA levels were normalized to 
18S and collagen type I levels compared to untreated controls. (B) Nicotine-treated 
fibroblasts were subjected to Western blot analysis using anti-collagen type I 
antibody or GAPDH, followed by secondary goat anti-rabbit IgG (IRDyeÒ). Protein 
bands were separated by native (collagen type 1) or SDS-PAGE (GAPDH) gel 
electrophoresis (8%) and quantified by densitometry. Collagen type I levels were 
elevated in the presence of nicotine (50 μg/ml). Significance was assessed using 
p values <0.05 obtained by two-tailed t-test.  
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Figure 11. Nicotine Stimulates Collagen Type I mRNA and Protein 
Expression at 48 and 72 Hours 
Vicary et. Al. 2016 
 
 (A) Primary lung fibroblasts were treated with nicotine (50 µg/ml) for up to 72 
hours. Nicotine induced a significant increase in collagen type I mRNA levels at 48 
hours. (B) Fibroblasts were treated with nicotine (50 µg/ml) for up to 72 hours. 
Collagen type I protein was increased at 48 and 72 hours by Western blot analysis. 
C: Purified rat-tail collagen. All experiments repeated at least 3 times. Significance 
was assessed using p values <0.05 obtained by two-tailed t-test. 
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Figure 12. Nicotine Induces Collagen Type I Through a7 nAChRs 
Vicary et. Al. 2016 
 
 (A) The absence of a7 nAChR was verified by mRNA and protein expression in 
the a7 nAChR deficient (a7KO) mice. (B) a7KO fibroblasts were exposed to 
nicotine for 24 hours. Nicotine failed to stimulate collagen type I mRNA expression 
in a7KO cells. (C) Nicotine-treated a7KO fibroblasts were subjected to Western 
blot analysis. Nicotine did not stimulate increased collagen deposition in a7KO 
fibroblasts. Experiments were repeated at least 3 times. Significance was 
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Figure 13. Nicotine Stimulates the Proliferation of Lung Fibroblasts via a7 
nAChRs 
Vicary et. Al. 2016 
 
Lung fibroblasts were cultured for up to 72 hours after transfection with control 
(Csi) or a7 nAChR siRNAs (a7si). At the appropriate times, the experiment was 
halted and live cells counted. Nicotine stimulated cell proliferation at 48 and 72 
hours when compared to control cells (*). Absence of the a7 nAChR induced 
significant proliferation compared to control cells at 72 hours (#). a7 nAChR 
siRNA inhibited the nicotine-induced response when compared to control cells at 
48 hours and significantly decreased proliferation at 72 hours (✣). Experiments 
were repeated at least 3 times. Significance was assessed using p values <0.05 
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Figure 14. Nicotine Stimulates the Proliferation of Lung Fibroblasts via 
Induction of ERK 
Vicary et. Al. 2016 
 
Fibroblasts were cultured for up to 72 hours with or without nicotine (50 µg/ml) in 
the presence or absence of PD98059 (MI, 50 µM), an inhibitor of MEK-1. Nicotine 
stimulated fibroblast proliferation at 48 hours, but the effect was most noticeable 
at 72 hours (*). The inhibitor PD98095 alone had a small effect on the proliferation 
of cells at 72 hours (#), but did inhibited the stimulatory effect of nicotine (✣). 
Experiments were repeated at least 3 times. Significance was assessed using p 





























Nicotine increases collagen expression in vivo  
To study the effects of nicotine in vivo, wildtype and a7KO mice were 
exposed to nicotine in their drinking water (100 µg/ml) for 12 weeks to test if the 
mechanisms described above are relevant to the situation in vivo. This model has 
been shown to increase nicotine levels in blood and tissue similar to those of heavy 
smokers without affecting body weight [217]. Lower concentrations (<1 µg/ml) of 
nicotine can be found in the blood of smokers, while higher concentrations (1-10 
µg/ml) are deposited in body tissues [216]. As depicted in  Figure 15, the lungs of 
mice exposed to nicotine showed increased collagen type I mRNA expression. 
a7KO mice showed an insignificant increase in collagen type I mRNA. Protein 
analysis showed an increase in collagen type I, p-ERK 1/2, and p-Smad3 protein 
expression when compared to control lungs (Figure 16). 
Histological analysis was performed on lung tissue harvested from 
untreated and nicotine-treated animals and found increased collagen deposition in 
wildtype mice treated with nicotine, noticeably around airway and vascular 
structures (red arrows) in tissues submitted to both Masson’s tri-chrome and Sirius 
red staining (Figure 17). The increase in collagen was confirmed by blinded scoring 
of unlabeled tissue slides by eight investigators. Nicotine also failed to stimulate 







 Figure 15. Nicotine Stimulates Collagen Type I mRNA Expression in Lung 
through the a7 nAChR In Vivo 
Vicary et. Al. 2016 
 
The lungs of wildtype mice exposed to nicotine (100 µg/ml) in the drinking water 
for 90 days were isolated for MRNA analysis, which showed an increase in 
collagen type I expression (Col (I)) in nicotine-treated wildtype mice, but not in a7 
nAChR deficient (a7KO) mice. Experiments were repeated at least 3 times. 





































Figure 16. Nicotine Stimulates p-Erk, p-Smad3 and Collagen Type I Protein 
Expression in Lung through the a7 nAChR In Vivo 
Vicary et. Al. 2016 
 
Protein analysis the lungs of wildtype mice exposed to nicotine (100 µg/ml) in the 
drinking water for 90 days showed increased p-Smad3, p-Erk 1/2 and collagen 
type I (Col(I)) when compared to control lungs. P-Erk, p-Smad3, and collagen type 
1 were all completed on the same gel, with the blot stripped between probings. 
Total Erk and Smad3 gels were run on a separate gel and stripped between 
probings. Experiments were repeated at least 3 times. Significance was assessed 















































Figure 17. Nicotine Stimulates Collagen Expression in Lung In Vivo 
Vicary et. Al. 2016 
 
 (A) The lungs of wildtype mice exposed to nicotine (100 µg/ml) in the drinking 
water for 90 days were inflated at standard pressure, fixed in formalin, paraffin-
embedded, and sectioned (5 μm) for histological analysis. Lung sections were 
stained for tri-chrome or Sirius Red/Fast Green. Arrows indicate increased 
collagen type I deposition (blue stain or Red stain) in wildtype animals exposed to 
nicotine. (B) The tri-chrome slides were blindly graded on a scale of 0-3 based on 
the intensity of collagen staining. Significance was assessed using p values <0.05 



























Figure 18. Nicotine-Induced Collagen Expression Mediated via a7 nAChRs 
in Lung In Vivo 
Vicary et. Al. 2016 
 
Lungs of a7KO mice exposed to nicotine (100 µg/ml) in the drinking water for 90 
days were inflated at standard pressure, fixed in formalin, paraffin-embedded, and 
sectioned (5 µm) for histological analysis. Nicotine treatment resulted in no 





Extracellular matrices derived from nicotine-treated lung fibroblasts 
stimulate monocytic cell expression of IL-1b 
 We then investigated whether matrices derived from nicotine-treated 
fibroblasts exert a differential effect on immune cells. For this, we cultured U937 
human monocytic cells atop of matrices derived from untreated or nicotine-treated 
fibroblasts; U937 cells expressed the human IL-1b gene promoter fused to a 
luciferase reporter gene [214]. As presented in Figure 19, we found that IL-1â 
gene transcription was increased about 2-fold when cultured atop of matrices 
derived from nicotine-treated fibroblasts when compared to cells cultured atop 
matrices derived from untreated fibroblasts. This effect appeared to be mediated 
by collagen binding to a2b1, a collagen integrin receptor, since anti-a2b1 
antibodies inhibited the induction of IL-1b (Figure 19). Importantly, IL-1b gene 
transcription was not increased in U937 cells cultured atop matrices derived from 
nicotine-treated a7KO lung fibroblast (Figure 20). Treatment of fibroblasts with 
MEK-1 inhibitor PD98059 or an a7 nAChR inhibitor MG 624 prior to exposure to 
nicotine blunted U937 IL-1b induction by the matrix (Figure 21, Figure 22). Lastly, 
this process might be relevant in vivo since whole lung MRNA from nicotine-treated 
mice showed elevated IL-1b gene transcription and staining by 







Figure 19. Matrices Derived from Nicotine-Treated Fibroblasts Stimulate IL-
1b Expression in Monocytic Cells Through the a2b1 Integrin Receptor 
Vicary et. Al. 2016 
 
Lung fibroblasts (5x104 cells/12 well) were treated with nicotine (50 µg/ml) for 120 
hours. Fibroblasts were removed by osmotic lysis, the plates were washed 
thoroughly, and human monocytic U937 cells expressing the human interleukin-1b 
gene promoter connected to a luciferase reporter gene were overlaid atop the 
fibroblast-derived matrix. Afterwards, expression of the IL-1b promoter was 
analyzed by luciferase assay. Collagen-containing matrices derived from nicotine-
treated fibroblasts stimulated monocytic cells to express the pro-inflammatory 
cytokine IL-1β (*). Furthermore, nicotine-treated fibroblast matrix induction of IL-1b 
was significantly decreased by anti-a2b1 integrin antibodies (#). Experiments were 
repeated at least 3 times. Significance was assessed using p values <0.05 

















































Figure 20. Pro-Inflammatory Matrices Derived from Nicotine-Treated 
Fibroblasts Mediated by a7 nAChR 
Vicary et. Al. 2016 
 
Wildtype and a7 nAChR deficient lung fibroblasts (a7KO) (5x104 cells/12 well) 
were treated with nicotine (50 µg/ml) for 120 hours. Fibroblasts were removed by 
osmotic lysis, the plates were washed thoroughly, and human monocytic U937 
cells expressing the human interleukin-1b gene promoter connected to a luciferase 
reporter gene were overlaid atop the fibroblast-derived matrix. Afterwards, 
expression of the IL-1b promoter was analyzed by luciferase assay. IL-1b gene 
transcription was not increased in U937 cells cultured on matrices derived from 
nicotine-treated a7 nAChR deficient primary lung fibroblast matrix over control. 
Experiments were repeated at least 3 times. Significance was assessed using p 

















































Figure 21. Pro-Inflammatory Matrices Derived from Nicotine-Treated 
Fibroblasts Blocked by a7 nAChR Inhibitor 
Vicary et. Al. 2016 
 
Wildtype lung fibroblasts (5x104 cells/12 well) were treated with nicotine (50 µg/ml) 
and MG 624, an a7 nAChR antagonist (10 µM), for 120 hours. Fibroblasts were 
removed by osmotic lysis, the plates were washed thoroughly, and human 
monocytic U937 cells expressing the human interleukin-1b gene promoter 
connected to a luciferase reporter gene were overlaid atop the fibroblast-derived 
matrix. Afterwards, expression of the IL-1b promoter was analyzed by luciferase 
assay. Fibroblasts treated with MG 624 concurrently with nicotine inhibited IL-1b 
expression without affecting baseline expression. Experiments were repeated at 
least 3 times. Significance was assessed using p values <0.05 obtained by 2-way 
















































Figure 22. Pro-Inflammatory Matrices Derived from Nicotine-Treated 
Fibroblasts Blocked by MEK-1 Inhibitor 
Vicary et. Al. 2016 
 
Wildtype lung fibroblasts (5x104 cells/12 well) were treated with nicotine (50 µg/ml) 
and PD98059, MEK-1 inhibitor (50 µM), for 120 hours. Fibroblasts were removed 
by osmotic lysis, the plates were washed thoroughly, and human monocytic U937 
cells expressing the human interleukin-1b gene promoter connected to a luciferase 
reporter gene were overlaid atop the fibroblast-derived matrix. Afterwards, 
expression of the IL-1b promoter was analyzed by luciferase assay. Fibroblasts 
treated with PD98059 concurrently with nicotine inhibited IL-1b expression without 
affecting baseline expression. Experiments were repeated at least 3 times. 
Significance was assessed using p values <0.05 obtained by 2-way ANOVA with 














































Figure 23. Nicotine Stimulates IL-1b Expression in Lung In Vivo 
Vicary et. Al. 2016 
 
(A) The lungs of mice exposed to nicotine (100 µg/ml) in the drinking water for 90 
days were isolated for mRNA analysis, which showed an increase in IL-1b gene 
transcription by RT-PCR. (B) Lungs from control and nicotine-treated mice were 
stained by immunohistochemistry for IL-1b. Increased staining was present in mice 
treated with nicotine. Experiments were repeated at least 3 times. Significance was 































Tobacco-related lung disease is an important health problem worldwide. 
Several studies suggest that tobacco exposure promotes lung tissue remodeling 
through oxidant stress, inflammation, and the induction of matrix-degrading 
proteases, among other mechanisms. The latter is supported by animal studies 
showing that overexpression of matrix metalloproteinase (MMP)-1 promotes the 
development of emphysema in transgenic mice, while the lack of MMP-12 is 
protective [219, 230]. Furthermore, alterations in MMPs and other proteases have 
been detected in humans with tobacco-related lung disease [231]. Unfortunately, 
this information has not yet translated into the development of effective therapeutic 
strategies. Here, we explore another mechanism of action, the induction of lung 
tissue remodeling through stimulation of extracellular matrix deposition. We 
hypothesized that nicotine, a major component of tobacco, is not only involved in 
tobacco addiction, but stimulates lung fibroblasts to release matrix components 
that affect the relative composition of the lung matrix. Consistent with this idea, we 
found that nicotine stimulates lung fibroblast expression and release of collagen 
type I up to 72 hours.  
Previously, we reported that nicotine stimulates the expression in lung of 
fibronectin, a matrix glycoprotein implicated in injury and repair [77]. However, 
fibronectin matrices are often considered 'transitional' matrices whose deposition 
does not necessarily lead to irreversible changes in tissue architecture in the 
absence of other factors. The discovery that nicotine also stimulates the deposition 
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of fibrillar collagens (this dissertation) is important because it suggests that the 
effects of nicotine on matrix composition may be more permanent. Collagen type I 
is highly expressed in injured lungs as demonstrated in acute lung injury, COPD, 
and chronic fibrotic lung disorders [232]. Additionally, collagen has been 
associated with extralobar pulmonary artery stiffening caused by chronic hypoxia 
[233], induction of epithelial-to-mesenchymal transition in non-small 
cell lung cancer cell lines [234], and stimulation of cell chemotaxis by its fragments 
[235].  
Considering the importance of the proposed mechanisms of action, we 
turned our attention to the pathways involved in stimulation of collagen expression. 
We found that nicotine affected collagen expression in lung fibroblasts by acting 
on a7 nAChRs. Several studies have implicated a7 nAChRs in lung branching 
morphogenesis and in the pathogenesis of lung cancer [236, 237]. More recently, 
a7 nAChRs were found to mediate the effects of nicotine in developing lungs [35, 
238]. Specifically, morphological airway abnormalities and airflow limitation were 
detected in the offspring of nicotine-treated wildtype animals, but not in animals 
lacking a7 nAChRs. Interestingly, and reminiscent to our work, collagen was found 
to be upregulated around the airways of animals exposed to nicotine. Based on 
the information presented here and the growing number of publications implicating 
a7 nAChRs in multiple disease states, it is reasonable to consider a7 nAChRs as 
promising targets for drug development to counteract the deleterious effects of 
tobacco. This is now possible considering that the technology to develop safe and 
effective agents that target nAChRs are currently available for human use [239]. 
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Another important finding was that nicotine also stimulated fibroblast 
proliferation, a process capable of further promoting tissue remodeling. This effect 
was also mediated via a7 nAChRs as demonstrated by the lack of response in 
cells silenced for a7 nAChRs. In prior work, we and others demonstrated that 
nicotine leads to ERK activation [77]. Consequently, we tested the role of ERK and 
found that a MEK-1/ERK inhibitor, PD98059, inhibited nicotine-induced fibroblast 
proliferation.  
To determine the potential relevance of our in vitro findings, we tested 
nicotine exposure in vivo. Previous studies have shown nicotine increases 
collagen type I expression in vivo in rhesus monkeys [90]. We exposed mice to 
nicotine in their drinking water for 8 weeks. When examined, the harvested lungs 
from nicotine-treated wildtype mice showed increased collagen deposition 
predominating around airway and vascular structures as determined by 
immunohistochemistry. Consistent with our in vitro findings, lung tissue also 
showed increased phosphorylation of ERK. We also detected increased 
phosphorylation of Smad3, a transcription factor known for mediating many of the 
pro-fibrotic effects of transforming growth factor-b. Increased Smad3 has been 
associated with collagen expression in cardiac and dermal fibroblasts [240, 241]. 
Our findings suggest that nicotine is capable of promoting fibronectin [77] 
and collagen type I (this report) deposition in lung without affecting the organ’s 
overall architecture. We refer to this process, which appears to be self-limiting, as 
“transitional remodeling”. Since deposition of new collagen fibrils in our model were 
not associated with dramatic alterations in lung architecture, how then do these 
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subtle changes in lung matrix composition affect the lung? We reasoned that these 
newly deposited collagen fibrils do not affect the lung in the absence of other 
injurious stimuli, but instead, may influence immune cell function after injury. 
Consistent with this idea, our lab has previously shown that purified collagen type 
I can robustly activate monocytic IL-1b expression [242]. In this report, we show 
that collagen-containing matrices derived from nicotine-treated fibroblasts are 
capable of activating monocytic cells and stimulating their expression of the pro-
inflammatory cytokine IL-1b. This pro-inflammatory event was inhibited by 
pretreating fibroblasts with antibodies against a2b1, a collagen-binding integrin 
[243], PD98059 (MEK-1 inhibitor), MG 624 (a7 nAChR inhibitor), or matrices 
derived from nicotine-treated a7KO primary lung fibroblasts when compared to 
control. Increased IL-1b gene expression was also detected in the lungs of 
nicotine-treated mice (Figure 23). In addition to monocytic cells, integrins also 
control immune responses in T cells. For example, integrin-mediated binding to 
collagen provides a co-stimulatory signal for T cell activation [244], resulting in 
increased proliferation and secretion of pro-inflammatory cytokines such as TNF-
a and IFN-g [245]. Thus, by promoting subtle alterations in matrix composition, 
nicotine may indirectly stimulate the exaggerated expression of pro-inflammatory 
cytokines (e.g., IL-1b) by immune cells recruited to the lung after injury, thereby 
helping perpetuate inflammation, a process considered important in the 
pathogenesis of tobacco-related lung disorders.  
Elements of lung transitional remodeling have also been demonstrated in alcohol-
exposed rats and mice [211, 246], alcoholic subjects [212], post-lung transplant 
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recipients [247], and aging mice [70]. However, the implications of lung transitional 
remodeling are unknown. It is presumed that if the stimulating agent is eliminated, 
a 'normal' matrix is restored. In contrast, persistence of the transitional matrix may 
lead to ineffective repair after injury through the induction of pro-inflammatory 
agents directly or via the release of matrix fragments [248]. We and others have 
suggested that these changes may explain the increased incidence and mortality 
observed for acute lung injury in alcoholics [212, 213], the predisposition to lung 
cancer in smokers [92, 249], the development of rejection after lung transplantation 
[247], and the worse outcomes observed in elderly patients with pulmonary 
disorders [70].  
 Additionally, it is important that we emphasize the implications of this 
research to understanding the potential impact (and safety) of e-cigarettes, an area 
that remains relatively unexplored. Consistent with this report, early studies 
suggested that e-cigarettes cause similar cell changes as those caused by tobacco 
exposure [250]. Considering this, in addition to serious concerns about their ability 
to serve as a gateway drug for smoking and current non-smokers, the use of these 
agents might pose a serious setback for global health with the use of e-cigarettes 
in adolescents, which has doubled yearly [251, 252]. 
 However, until further studies are performed, these statements remain 
highly speculative. Booth et al., recently published a technique to isolate acellular 
lungs, which could provide the methods to study this interaction in a transitional 
matrix lung [59]. Nevertheless, the idea that lung transitional remodeling may 
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precede processes such as COPD, acute lung injury and pulmonary fibrosis, 
among other disorders, is tantalizing and testable.  
 In summary, chronic nicotine exposure in mice results in lung matrix 
remodeling characterized by increased collagen type I expression/deposition in 
lung as well as phosphorylation of ERKs and Smad3. In the absence of injury, this 
subtle change in matrix composition does not affect the overall lung architecture, 
but may promote exaggerated inflammatory (e.g., induction of IL-1b by immune 
cells) and repair (e.g., fibroproliferation) responses after injury. These events 
appear to be mediated via a7 nAChRs, which may represent promising targets for 
intervention if lung transitional remodeling is proven to be a pre-disease 










Smoking is considered the most important contributing factor in the 
development of fibrosing lung disorders including idiopathic pulmonary fibrosis, 
where over half of patients with the disease are smokers or ex-smokers [23, 25]. 
IPF is characterized by progressive lung tissue remodeling and affects over 
100,000 Americans [1]. 
How smoking contributes to tissue remodeling is unclear and work in this 
area has been hampered by the complex nature of tobacco smoke, which contains 
over 7,000 compounds [26, 27]. Recently, attention has turned to the potential role 
of nicotine, an alkaloid present in tobacco, known for driving the addictiveness of 
cigarettes. Nicotine has been shown to affect several biological processes 
including cell apoptosis, migration, invasion, angiogenesis, inflammation and 
immunity [33]. Additionally, the Roman lab has previously demonstrated that
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nicotine stimulates the proliferation of primary lung fibroblasts as well as their 
production of fibronectin, a matrix glycoprotein implicated in tissue injury and 
disrepair [46, 77]. I have also found that nicotine promotes the expression and 
deposition in lung of collagen type I, a fibrillar collagen highly expressed in 
maladaptive repair (Chapter 3). Thus, it appears that nicotine is not just 
responsible for tobacco dependence, but might also contribute to the pathogenesis 
of chronic lung disease. However, the exact mechanisms by which nicotine 
contributes to the pathophysiology of pulmonary fibrosis is unknown. Thus, we set 
out to investigate this in a murine model of lung fibrosis. 
Several models have been used to study pulmonary fibrosis, yet none of 
these models have accurately reproduced the human condition at this time. 
Bleomycin-induced lung fibrosis is the most commonly used model use to 
investigate the mechanisms that lead to tissue remodeling after lung injury [160]. 
Studies performed in the bleomycin model of lung injury have provided some 
insight into the role of cigarette smoke. Guinea pigs exposed to cigarette extract 
for example, having worse lung fibrosis than the bleomycin treatment alone group 
[175]. Similarly, bleomycin-induced alveolar architecture derangement was 
enhanced by cigarette smoke in hamsters [173]. In another study, however, 
cigarette smoke exposure failed to enhance bleomycin-induced lung fibrosis in 
rats, but cigarette smoke exposure was not initiated till post bleomycin instillation 
[176]. Thus, there appears to be a role for tobacco exposure in pulmonary fibrosis, 
but much remains to be elucidated. To date, no studies have been published on 
the role of nicotine in bleomycin-induced lung fibrosis. We hypothesized that 
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increased baseline levels of fibronectin and collagen due to nicotine exposure, 
creating a transitional matrix, would increase bleomycin-induced lung fibrosis.  
Nicotine induced fibronectin and a-SMA expression in pulmonary 
fibroblasts and mice. The nicotine induction was ablated in a7 nAChR deficient 
fibroblasts and mice. Additionally, nicotine induced ECM production indirectly, with 
bronchoalveolar lavage fluid from nicotine-treated mice increasing fibronectin 
expression in fibroblasts. 
To investigate the role of this transitional matrix in pulmonary fibrosis, 
wildtype and a7 deficient mice (a7KO) were treated with nicotine for 90 days, then 
instilled with bleomycin and euthanized 21 days later. Mice treated with nicotine 
and bleomycin had significantly more fibrosis when compared to bleomycin alone, 
but the role of a7 nAChRs in mediating this effect was less clear, with a7KO mice 
having increased fibrosis at baseline when compared to wildtype, but nicotine 
exposure lowered fibrosis in a7KO mice to wildtype levels. Additionally, I 
investigated the mechanobiology effects of nicotine-induced fibrosis on the lung, 
but no significant differences in lung stiffness were detected between untreated 
and nicotine-treated mice instilled with bleomycin. In conclusion, subtle changes 









Nicotine stimulates fibronectin and a-SMA expression in vitro and in vivo via 
a7 nAChRs 
Primary lung fibroblasts from wildtype and a7KO mice were cultured with 
nicotine for 24 hours and isolated for protein and mRNA analysis. As depicted in 
Figure 24 and Figure 25, nicotine stimulation enhanced fibronectin and a-SMA 
expression in wildtype lung fibroblasts, but was absent in a7KO cells. In Vivo, 
nicotine stimulated fibronectin and a-SMA expression in the lungs of wildtype mice, 
but not in a7KO mice (Figure 26 and Figure 27). Similarly, transgenic mice 
expressing the human fibronectin gene fused to a luciferase reporter gene were 
exposed to nicotine in their drinking water for up to 90 days. Increased expression 
of luciferase (i.e. fibronectin) throughout the lung indicates the induction of 
fibronectin deposition in lung is due to increased expression in several resident 
lung cell types (Figure 28). Furthermore, the ability of the bronchoalveolar lavage 
fluid of nicotine-treated animals to stimulate fibronectin expression was 
investigated. As depicted in Figure 29, BAL fluid harvested from nicotine-treated 
animals stimulates fibronectin expression in otherwise untreated NIH3T3 lung 
fibroblasts. We found that this effect appears specific since the BAL fluid of 
nicotine-treated animals did not stimulate THP monocytes to express MMP-9, an 





Figure 24. Nicotine Stimulates Fibronectin Protein Expression Through a7 
nAChRs 
Vicary et. Al., Unpublished 
 
Fibroblasts were harvested from the lungs of wildtype (WT) and a7 nAChR 
deficient mice (a7KO) and cultured in the presence or absence of nicotine (N) (50 
µg/ml) for 48 hours and isolated for western blot analysis. Actin was used for 
normalization purposes. Results expressed as mean optical density (OD) units. 
Nicotine stimulated fibronectin production in wildtype cells, but failed to induce a 
significant amount of fibronectin in the a7KO fibroblasts. Experiments were 
repeated at least 3 times. Significance was assessed using p values <0.05 




Figure 25. Nicotine Stimulates a-Smooth Muscle Actin (a-SMA) mRNA 
Expression 
 
Vicary et. Al., Unpublished 
 
Fibroblasts were harvested from the lungs of wildtype mice and cultured in the 
presence or absence of nicotine (N) (50 µg/ml) for 48 hours and isolated for mRNA 
analysis. Actin was used for normalization purposes. TGF-b1 (TGF) served as a 
positive control. Nicotine stimulated a-SMA production in wildtype fibroblasts. 
Experiments were repeated at least 3 times. Significance was assessed using p 




Figure 26. Nicotine Stimulates mRNA Fibronectin Expression through a7 
nAChRs In Vivo 
Vicary et. Al., Unpublished 
 
Wildtype (WT) and a7 nAChR deficient (a7KO) mice were exposed to nicotine 
(100 µg/ml) in the drinking water for 90 days. Lungs were isolated for mRNA 
analysis. b-actin was used for normalization purposes. Nicotine stimulated 
fibronectin production in wildtype lungs, but not in a7KO mice. Experiments were 
repeated at least 3 times. Significance was assessed using p values <0.05 




Figure 27. Nicotine Stimulates a-SMA Protein Expression through a7 
nAChRs In Vivo 
Vicary et. Al., Unpublished 
 
Transgenic mice expressing the human fibronectin gene fused to a luciferase 
reporter gene were exposed to nicotine (100 µg/ml) in the drinking water for 90 
days. Lungs were isolated for protein analysis. b-actin was used for normalization 
purposes. Results expressed as mean optical density (OD) units. Nicotine 
stimulated a-SMA production in wildtype lungs, but not in a7KO mice. Experiments 
were repeated at least 3 times. Significance was assessed using p values <0.05 




Figure 28. Nicotine Stimulates Fibronectin Expression through a7 nAChRs 
In Vivo 
Vicary et. Al., Unpublished 
 
Transgenic mice expressing the human fibronectin gene fused to a luciferase 
reporter gene were exposed to nicotine (100 µg/ml) in the drinking water for 90 
days. Lungs were isolated for histology. Increased expression of luciferase 
(connected to fibronectin gene) was detected throughout the lung indicating that 
the previously reported induction of fibronectin protein deposition in lung is due to 
increased gene expression in several resident lung cell types. Experiments were 
repeated at least 3 times.   




Figure 29. Bronchoalveolar Lavage (BAL) Fluid from Nicotine-Treated Mice 
Induced Fibronectin Expression in NIH3T3 Fibroblasts 
Vicary et. Al., Unpublished 
 
(A) BAL fluid was harvested from wildtype mice exposed to nicotine (100 µg/ml) in 
the drinking water for 90 days. BAL fluid was cultured with NIH3T3 fibroblasts 
transfected with the human fibronectin promoter connected to a luciferase reporter 
gene for 24 hours. BAL fluid from nicotine-treated mice induced significant 
expression of fibronectin. (B) BAL fluid did not stimulate the expression of the 
MMP-9 promoter in THP-1 cells transfected with a MMP-9 promoter-luciferase 
construct. B: baseline; C: BAL fluid from control animals; N: BAL fluid from nicotine 
treated animals. Experiments were repeated at least 3 times. Significance was 
assessed using p values <0.05 obtained by two-tailed t-test.  
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Nicotine enhances bleomycin-induced lung fibrosis through a7 nAChRs 
 Having examined the effects of nicotine on fibronectin and a-SMA 
expression in vitro and in vivo, we turned our attention to its effects on bleomycin-
induced lung fibrosis. Untreated and nicotine-treated animals were administered 
bleomycin (1.0 U/kg) intratracheally to promote the development of fibrosis. As 
hypothesized, bleomycin-induced lung fibrosis was increased in nicotine treated 
mice as observed by histology (Figure 30). However, the role of a7 nAChRs in 
mediating the increased fibrosis seen in nicotine-treated mice is unclear. a7KO 
mice treated with bleomycin alone had increased fibrosis at when compared to 
wildtype mice treated with bleomycin alone, but was dissipated with nicotine-
treatment (Figure 30).  
 
Creation of an ex vivo model and determination of lung stiffness 
Lungs from wildtype control and nicotine-treated mice instilled with 
bleomycin mice were decellularized by perfusions of DI solution (dH20 with 1% 
Antibiotic Antimitotic Solution), 0.1% Trition X-100, 2% Na deoxycholate, 1M 
NaCl, and DNAse solution and embedded in 6% Seaprep Ultra Low Agarose 
(Figure 31). Acellular lung sections were cut in a vibratome and stained for 
hematoxylin, tri-chrome, and immunostaining. Lack of DAPI staining showed 




Acellular lungs from bleomycin and bleomycin and nicotine treated mice 
were tested for possible mechanical property differences by atomic force 
microscopy. A force map of each sample was conducted and stiffness 
measurements (pascals) were averaged. There were no significant differences in 
lung stiffness between bleomycin and bleomycin and nicotine treated mice due to 






























Figure 30. Nicotine Induces Bleomycin-Induced Fibrosis 
Vicary et. Al., Unpublished 
 
The lungs of wildtype and a7 nAChR deficient (a7KO) mice exposed to nicotine 
(100 µg/ml) in the drinking water for 120 days. Bleomycin was administered 
intratracheally at a dose of 1.0 U/kg body weight. Surviving animals were sacrificed 
at 21 days post-bleomycin. (A) The lungs were processed and stained by 
Masson’s trichrome staining. (B) Slides were blindly graded with PBS control lungs 
scored as 1 on the Ashcroft scale. Nicotine caused an increase in bleomycin-
induced pulmonary fibrosis at 21 days in WT mice. Nicotine’s affects were not 
present in a7KO mice, but interestingly, a7KO mice had increased fibrosis with 
bleomycin alone when compared to wildtype mice. Experiments were repeated at 
least 3 times. Significance was assessed using p values <0.05 obtained by two-

































Figure 31. Lung Decellularization 
Vicary et. Al., Unpublished 
 
(A) Lungs were decellularized by perfusing 3 cc of H20 solution into the right 
ventricle of the heart and trachea. Perfusions of Triton X-100, deoxycholate, NaCl, 
DNase, and peracetic acid followed with incubations in each solution performed at 
4oC on a rocker. Acellular lungs are embedded into low temperature SeaPrep™ 
agarose and cut using a vibratome. (B) Acellular lung sections from control and 
bleomycin-treated mice. Bleomycin-treated sections showed increased density of 
whiteness (i.e. ECM proteins).  
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Figure 32. Verification of Acellular Lung 
Vicary et. Al., Unpublished 
 
Acellular and normal lung sections from wildtype mice were stained using 
hematoxylin and eosin, Masson’s tri-chrome, or immunohistochemistry. 
Immunostaining was carried out with control antibodies and antibodies against 
Fibronectin, DAPI, and IgG. Staining showed removal of cellular material with 


























Figure 33. Nicotine Did Not Increased Stiffness of Bleomycin-Treated 
Lungs 
Vicary et. Al., Unpublished 
 
Acellular lungs from bleomycin alone and bleomycin and nicotine treated mice 
were tested for stiffness by atomic force microscopy. A force map of each sample 
was conducted and stiffness measurements (pascals) were averaged. There were 
no significant differences in lung stiffness between bleomycin and bleomycin and 
nicotine treated mice due to the large variation in stiffness within each lung. 





































Smoking is considered the most significant contributing factor in several 
pulmonary diseases, including IPF, but the mechanisms by which these factors 
induce disease need to be elucidated [23, 25]. The pathogenesis of pulmonary 
diseases is intriguing with some patients diagnosed with conditions such as IPF 
and chronic obstructive pulmonary disease after a relatively brief smoking history, 
while others can smoke for years with no detrimental health effects. This could be 
due to the requirement of a second hit or multiple chemical exposures to induce 
fibrogenesis. Supporting, no studies have shown nicotine alone can induce fibrosis 
or any other remodeling disease. 
Here the data suggesting that nicotine creates an altered ECM state in the 
lung that accelerating fibrosis caused by a second challenge. Nicotine induces a 
transitional matrix marked by increased fibronectin, collagen type I, and a-SMA 
expression (Figure 17 and Figure 28) [77]. Fibronectin, collagen, and a-SMA are 
extracellular matrix proteins implicated in tissue injury and disrepair [46, 77, 253]. 
This induction of ECM proteins is mediated by a7 nAChRs (Figure 26 and Figure 
27). Additionally, immunohistochemistry analysis showed increased expression of 
fibronectin throughout the lung, indicating that nicotine is able to induce fibronectin 
expression in several resident lung cell types, not just fibroblasts, which are 
normally considered the main producer of ECM proteins (Figure 28). Interestingly, 
nicotine can also induce fibronectin in an indirect fashion, via BAL fluid (Figure 29). 
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Although others and I have shown that nicotine induces ECM proteins, they are at 
a subclinical level, not marked by structural changes (Figure 29).  
Investigating the role of nicotine-induced transitional matrix in pulmonary 
fibrosis induced by injury, mice were exposed to nicotine for 90 prior to bleomycin 
instillation. We found nicotine significantly induced bleomycin-induced fibrosis in 
wildtype mice (Figure 30). This suggests that the increased collagen and 
fibronectin deposition caused by nicotine exposure accelerated fibrosis instigated 
by a secondary challenge. The role of a7 nAChRs in mediating this effect is 
unclear. Previously, lack of a7 nAChR has been shown to cause increased 
fibroblast proliferation and airway hyperplasia in a7 nAChR deficient mice [238, 
254]. This may explain the increased fibrosis seen in untreated a7KO mice when 
compared to wildtype mice (Figure 30). a7KO mice treated with nicotine ablated 
the increased fibrosis, although the mechanism is unclear.  
 Lastly, we investigated potential changes in the mechanobiology of the lung 
caused by nicotine exposure. The lung continuously expanding and contracting, 
exposes pulmonary cells to rhythmic stress and strain, which are necessary for 
cellular homeostasis [201]. Changes in tissue stiffness have been shown in COPD 
and IPF [59, 191-194, 255, 256]. Acellular lungs were isolated from bleomycin 
alone and nicotine and bleomycin-treated mice. Removal of cellular material while 
maintaining ECM structure was verified by lack of DAPI staining (Figure 32). Using 
atomic force microscopy, no differences in lung stiffness were detected between 
the two groups (Figure 33). This was due to the large variability in lung stiffness 
seen within lungs. 
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 In conclusion, we present evidence that nicotine induces subtle changes in 
lung composition through ECM induction via a7 nAChRs. This increase in proteins 
causes significant acceleration of pulmonary fibrosis caused by injury, but the role 
of a7 nAChR and lung stiffness are unclear. Clinically, a7 nAChR or ECM 
degradation might pose promising targets for the prevention of pulmonary fibrosis 




THE IMPACT OF CHRONIC NICOTINE EXPOSURE ON SURVIVAL AFTER 




Approximately 40 million Americans smoke cigarettes, costing the U.S. 
economy over $175 billion a year in healthcare expenditures [257, 258]. Tobacco 
smoke is a risk factor for several pulmonary diseases characterized by tissue 
remodeling, including idiopathic pulmonary fibrosis (IPF). Studying how tobacco 
smoke promotes these diseases is hindered by tobacco smoke’s complexity, 
containing over 7,000 chemicals [26, 27].  
Due to the rapid rise of e-cigarettes, research has recently began focusing 
on nicotine, the main addictive component in tobacco smoke [259, 260]. Nicotine 
interacts with cells via cholinergic receptors capable of signal transduction termed 
nicotinic acetylcholine receptors (nAChRs) [35, 238]. These receptors are 
multimeric acetylcholine-triggered channel proteins that form homomeric and 
heteromeric a and b chain pentameters [261].  
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During embryogenesis, nicotine-a7 nAChR interactions influence lung 
branching morphogenesis and result in airway thickening and dysfunction [34, 35, 
91]. Nicotine has been shown to induce ECM proteins (e.g. collagen type I, 
fibronectin, a-SMA), a hallmark of tissue remodeling in lung diseases [47, 77]. This 
ECM induction is mediated by a7 nAChRs in lung fibroblasts (Figure 10, Figure 
12, and Figure 24) [77]. Nicotine cannot cause clinical remodeling (i.e. fibrosis) 
alone, thus, we set out to investigate the effects of chronic nicotine exposure after 
a secondary insult using the model of bleomycin-induced lung injury.  
Bleomycin instillation generates free radicals injuring DNA [262, 263], lipids 
[264], and proteins [265], which drive robust inflammation the first two weeks 
closely resembling acute lung injury (ALI) [171, 266, 267].This phase is followed 
formation of pulmonary fibrosis during the third week post-instillation [171]. 
Pulmonary fibrosis has historically been characterized by extensive extracellular 
remodeling, but more recent research has connected immune responses [118-
121]. Activated fibroblasts being highly responsive to additional growth factors/pro-
inflammatory cytokines [118, 119]. This mechanism suggests a capacity for the 
immune system to accelerate fibroblast-mediated pulmonary remodeling. 
Additionally, oxidants have implicated in pulmonary fibrosis [146]. 
Superoxide, one of the main oxidants in the lung, has been shown to stimulate 
fibroblasts to secrete collagens, a hallmarks of pulmonary fibrosis [268]. To protect 
against oxidant damage, the lung has a high abundance of anti-oxidants, including 
superoxide dismutases (SODs). Overexpression of superoxide dismutase 3 
(SOD3) was protective against fibrosis in the bleomycin model [153]. How tobacco 
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(i.e. nicotine) affects anti-oxidants is still being elucidated. Some have postulated 
that cigarette smoke promotes the induction of oxidant stress [146]. In rats, nicotine 
alone has been shown to affect the oxidative state of the lung by increasing the 
activity of superoxide dismutase, an important protective mechanism in lung [151, 
152].  
We hypothesized that nicotine would augment pulmonary injury in wildtype 
bleomycin-treated animals and that this effect would be ablated in a7 nAChR 
deficient animals (a7KO). Mice began dying ~12 days post bleomycin instillation, 
but surprisingly we found that nicotine was protective against death, and this 
protective effect was dependent on the presence of a7 nAChR. Additionally, an 
increase in the anti-oxidant SOD1 expression and activity was detected with 
nicotine-treated wildtype mice, suggesting a potential mechanism of protection. In 
conclusion, our studies suggest that nicotine-a7 nAChR interactions could play an 




Nicotine is protective in high-dose bleomycin–induced lung injury by acting 
on a7 nAChRs 
 To test the role of chronic nicotine exposure in the bleomycin model, 
wildtype and a7KO mice were exposed to nicotine (100 µg/ml) in their drinking 
water for 90 days followed by intratracheal instillation of bleomycin (2.0 U/kg). This 
dose of bleomycin was associated with significant mortality with 80% of animals 
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dying within 12 days after bleomycin instillation (Figure 34A). Interestingly, nicotine 
exposure was protective with 40% fewer animals dying in response to bleomycin.  
Even more interesting was the observation that the protective effects of nicotine 
appeared dependent on a7 nAChR expression since animals deficient in this 
receptor also experienced high mortality despite nicotine treatment (Figure 34B). 
Similar observations were made in animals exposed to nicotine for a longer term 
(207 days) (Figure 34C).  
 
Nicotine did not affect bleomycin-induced weight loss or lung fibrosis 
 We then set out to investigate the mechanisms responsible for the 
protective effects of nicotine. First, we examined the body weight of the animals 
and found that, as predicted, bleomycin-induced weight loss, but this was not 
affected by nicotine exposure or a7 nAChR expression (Figure 35). Second, we 
examined the histology of the lungs of the surviving mice. We noted no differences 
between the groups, independent of treatment (Figure 36 and Figure 37).  
 
Inflammation does not appear to play a role in the protective role of nicotine 
in bleomycin–induced lung injury  
Third, we examined the mRNA expression of soluble mediators involved in 
inflammation (IL-1b and TNF-a) and fibrosis (TGF-b) in the surviving animals. As 
depicted in Figure 38, both nicotine and bleomycin were observed to stimulate the 
expression of all three mRNAs, but the expression pattern did not suggest 
inflammation as the cause of nicotine-induced protection. Interestingly, lack of a7 
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nAChR was associated with increased expression of all three mRNAs at baseline, 
but the general pattern of mRNA expression was not greatly affected by nicotine 
or bleomycin.  
 
Nicotine induces superoxide dismutase 1 (SOD1) and appears to be 
mechanism of the protection in high-dose bleomycin–induced lung injury  
 Fourth, considering several lines of evidence implicating superoxides as 
one of the ROS that mediate lung injury, we examined SOD expression [146]. 
SOD1 has been shown to mediate asbestosis-induced pulmonary fibrosis through 
production of H2O2 [269]. In vitro, we found that nicotine stimulates the expression 
of SOD1 in cultured primary lung fibroblasts (Figure 39). Additionally, presented in 
Figure 40A and B, nicotine and bleomycin were found to increase SOD1 mRNA 
expression in wildtype, but was absent in a7 nAChR KO mice. Lastly, we found 
nicotine-treated mice had increased SOD activity when compared to non-nicotine-











Figure 34. Nicotine Induces Protection Against Dead Caused by Bleomycin-
Induced Lung Injury 
Vicary et. Al., Unpublished 
 
(A and B) Wildtype and a7 nAChR deficient (a7KO) mice were exposed to nicotine 
(100 µg/ml) in the drinking water for 107 days then instilled with intratracheal 
bleomycin (2.0 U/kg). Death occurred in 80% of wildtype mice at 12 days post 
instillation. Nicotine induced significant protection in wildtype mice but was absent 
in a7KO mice. Wildtype and nicotine-treated mice had 0% mortality, with wildtype 
survival line hid behind the nicotine treated mice. (C) Wildtype and a7KO mice 
were exposed to nicotine (100 µg/ml) in the drinking water for 207 days then 
instilled with intratracheal bleomycin (2.0 U/kg). Death occurred in 80% of wildtype 
mice at 12 days post instillation. Nicotine induced protection in wildtype mice but 
there was also small amount of protection in a7KO mice.  
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Figure 35. Nicotine-Treatment Does Not Affect Bleomycin-Induced Weight 
Loss 
Vicary et. Al., Unpublished 
 
(A and B) Wildtype and a7 nAChR deficient (a7KO) mice were exposed to nicotine 
(100 µg/ml) in the drinking water for (A) 107 or (B) 207 days then instilled with 
intratracheal bleomycin (2.0 U/kg). There was no significant difference in weight 
lost between the groups tested in A and B. Experiments were repeated at least 3 
times. Experiments were repeated at least 3 times. Significance was assessed 
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Figure 36. Nicotine-Induced Protection (107 Days) Against Bleomycin-
Induced Death Showed No Differences in Fibrosis 
Vicary et. Al., Unpublished 
 
(A) Surviving mice from Figure 34A and B had their lungs inflated at standard 
pressure, fixed in formalin, paraffin-embedded, and sectioned for histological 
analysis. Lung sections were stained with hematoxylin and eosin. (B) The tri-
chrome slides were blindly graded on the Ashcroft scale. No significance was 
found between groups. Experiments were repeated at least 3 times. Significance 
was assessed using p values <0.05 obtained by 2-way ANOVA with Bonferroni 
posttest.  



































Figure 37. Nicotine-Induced Protection (207 Days) Against Bleomycin-
Induced Death Showed No Differences in Fibrosis 
Vicary et. Al., Unpublished 
 
 (A) Surviving mice from Figure 34C had their lungs inflated at standard pressure, 
fixed in formalin, paraffin-embedded, and sectioned for histological analysis. Lung 
sections were stained with hematoxylin and eosin. (B) The tri-chrome slides were 
blindly graded on the Ashcroft scale. No significance was found between groups. 
Experiments were repeated at least 3 times. Significance was assessed using p 
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Figure 38. Nicotine-Induced Protection Against Bleomycin-Induced Death 
Not Connected to Inflammation 
Vicary et. Al., Unpublished 
 
(A) We examined the mRNA expression of soluble mediators involved in 
inflammation (IL-1b and TNF-a) and fibrosis (TGF-b) in the surviving animals. In 
wildtype mice, both nicotine and bleomycin stimulated the expression of all three 
mRNAs, but the expression pattern did not suggest inflammation as the cause of 
nicotine-induced protection. Untreated wildtype controls normalized have 
expression equal to 1. (B) Lack of a7 nAChR was associated with increased 
expression of all three mRNAs at baseline, and this general pattern of expression 
was not greatly affected by nicotine or bleomycin. Untreated a7KO controls 
normalized have expression equal to 1. Experiments were repeated at least 3 
times. Significance was assessed using p values <0.05 obtained by 2-way ANOVA 
with Bonferroni posttest. a = compared to control, b = compared to nicotine, c = 








































































Figure 39. Nicotine-Induces Superoxide Dismutase 1 (SOD1) mRNA 
Expression 
Vicary et. Al., Unpublished 
 
Wildtype lung fibroblasts were cultured in nicotine (50 µg/ml) for 24 hours and then 
isolated for mRNA. SOD1 expression was significantly upregulated in nicotine-
treated fibroblasts. Experiments were repeated at least 3 times. Significance was 

































Figure 40. Nicotine-Induces SOD1 mRNA Expression and Activity In Vivo 
Vicary et. Al., Unpublished 
 
(A and B) Whole lung mRNA isolated from wildtype and a7KO mice treated with 
nicotine and/or bleomycin showed significant induction of SOD1 in all three 
treatment groups. Nicotine and bleomycin had significantly more expression then 
nicotine or bleomycin alone. Untreated wildtype and a7KO control mice were 
normalized to have expression equal to 1. Induction of SOD1 was blunted in the 
a7KO groups. Significance was assessed using p values <0.05 using 2-way 
ANOVA with Bonferroni posttest. a = compared to control, b = compared to 
































































































Figure 41. Nicotine-Induces SOD1 Activity In Vivo 
Vicary et. Al., Unpublished 
 
In vivo activity of superoxide dismutase was determined using an SOD enzymatic 
assay. Nicotine-treated mice significantly increased SOD activity when compared 
to control mice. Experiments were repeated at least 3 times. Significance was 


































































































We set out to investigate the impact of chronic nicotine exposure on 
bleomycin-induced lung injury. It is well known that bleomycin-induced tissue injury 
is greatly affected by method of injection, timing, and batch of drug. Routes of 
injection include inhalational, intratracheal, intraperitoneal, intravenous, and 
subcutaneous [270]. During the first two weeks after injection, bleomycin induces 
a robust inflammatory response including IL-1b, TNF-a and IL-16 [271]. Bleomycin 
also induces an intense oxidant response characterized by increased SOD, 
catalase, glutathione peroxidase malondialdehyde [272-277]. 
Considering reports by us and others showing nicotine induces extracellular 
matrix proteins involved in pulmonary fibrosis, we predicted that nicotine would 
worsen outcomes [35, 77, 238]. Surprisingly, we found that chronic nicotine 
exposure induced protection against death in mice exposed to bleomycin (Figure 
34). Perhaps the most important observation we found was that the protective 
effect of nicotine was mediated through a7 nAChRs since the mortality of animals 
lacking these receptors was the same as that for wildtype animals. Thus, activation 
of cholinergic signaling through a7 nAChRs resulted in protection against death in 
the setting of bleomycin. 
The protective effect of nicotine was early (12 days) after bleomycin 
administration suggesting effects during the late inflammatory stage of injury and 
not related to the fibrotic process seen later in these animals (Figure 36). Thus, we 
speculated that nicotine affect the inflammatory response. Nicotine has been 
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shown to have anti-inflammatory effects on macrophages by reducing the 
expression of pro-inflammatory cytokines [278-280]. In contrast, we found 
increased IL-1b and TNF-a expression in the lungs of nicotine-treated animals, 
suggesting nicotine may stimulate inflammatory cytokines in lung (Figure 38). The 
cellular origins of these cytokines were not investigated during these studies. 
However, the a7 nAChR seems to play a role in mediating an inflammatory 
response, with a7KO mice having no or reduced induction of inflammatory 
cytokines IL-1b and TNF-a. 
Lastly, investigating other potential mechanisms of protection, we found an 
increase in SOD1 expression and activity associated with nicotine exposure 
(Figure 39 and Figure 40). Previous research supports the protective effects of 
anti-oxidants, with overexpression of SOD and inhalation of lecithinized SOD 
shown to be protective against bleomycin-induced fibrosis [153, 281]. Additionally, 
SOD1 has been shown to attenuate DNA breakage induced by bleomycin in vitro 
[282]. Other SODs, such as EC-SOD (SOD 3) are also protective against 
bleomycin-induced fibrosis [153]. This mechanism may also be relevant clinically, 
since Pirfenidone, an FDA approved drug for pulmonary fibrosis, has been shown 
to rescue SOD loss in renal proximal tubular cells [283]. 
It should be highlighted that we only tested chronic nicotine exposure, which 
is likely to elicit responses that differ from those triggered by acute nicotine 
exposure. Not much research has been conducted on acute nicotine exposure, but 
the lung is a short-term depot for nicotine after exposure, with the lungs showing 
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higher levels than the brain [28]. Additionally, acute nicotine exposure raises 
cotinine levels similar to chronic exposure, but doesn’t affect lung function [284].  
Although these observations point to the involvement of a7 nAChRs and 
anti-oxidants mediating the protective effects of nicotine, we were unable to 
determine exactly how chronic nicotine exposure protected mice against death 




A NEW DIAGNOSTIC PHYSIOLOGICAL FORMULA FOR EARLIER 




Idiopathic pulmonary fibrosis (IPF) is defined progressive bilateral fibrotic 
changes of unknown etiology [1, 5]. IPF affects over 100,000 patients in the U.S. 
and hundreds of thousands across the world with a dismal survival rate of 3 years 
from the time of diagnosis [2, 6, 285]. IPF is difficult to diagnose; characterized by 
impaired lung function and presence of usual interstitial pneumonia, often needing 
several doctors for confirmation [11, 12, 286]. The number of IPF cases appears 
to be increasing; due in part to the aging population, increasing patient and 
physician awareness, and improving computer tomography (CT) imaging [10]. In 
addition to diagnosis, monitoring IPF severity and progression is critical to 
decision-making for treatment, management and timing for lung transplantation. 
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Currently two new drugs to treat IPF are on the market, but they are not 
curative, only slowing the progression of fibrosis in some individuals [287, 288]. 
The definitive treatment for IPF is lung transplantation in individuals who qualify 
[5]. The progression of fibrosis varies greatly between patients, with some 
remaining stable for years, while others decline rapidly [5]. Determination of 
disease progression in IPF is multifactorial including reported and objective 
measures of exertional tolerance, radiological changes, and measurement of lung 
function [289]. Early evidence of pulmonary fibrosis might be manifested by a 
decrease in lung capacity and reduced diffusing capacity for carbon monoxide, 
which is typical of fibrosing lung disorders. A six-minute walk test (6MWT) with a 
portable oximeter should also be considered as hypoxemia may only be detected 
during exertion in early stages [5, 290]. Chest imaging is important in confirming 
IPF diagnosis with high-resolution computed tomography (HRCT) being the best 
imaging for IPF confirmation.  
Forced vital capacity (FVC) is the one spirometry measure of lung function 
testing that best correlates with disease progression [291, 292]. A 10% decline in 
FVC from the baseline measure at diagnosis is considered a significant worsening 
and is a major end-point in clinical trials in IPF [50, 51]. The FVC alone, however, 
is a surrogate only for the restrictive impairment produced by lung fibrosis and 
manifested through increased elastic recoil of the fibrotic tissue compared to 
normal lung.  
There has been little attention paid to airflow abnormalities in IPF and other 
lung fibrosing disorders from a clinical standpoint. In addition to FVC, spirometry 
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can also measure airway obstruction by forced expiratory volume in 1 second 
(FEV1) [293]. A FEV1/FVC ratio (Tiffeneau-Pinelli index) has been found to 
correlate with survival in IPF, but is rarely used clinically [294, 295]. Despite the 
lack of attention on airflow changes in IPF, a few studies have suggested that 
airflow abnormalities may be a key determinants of survival in this disease [296-
298]. High lung elastic recoil is believed to make it difficult to blow expiration fast 
and consequently makes FEV1/FVC high [299]. Indeed, bronchiolar fibrosis and 
inflammation seen in histological specimens of individuals with IPF and other forms 
of pulmonary fibrosis have been known for decades and correlate with impairments 
in airflow [300-302]. Brown and colleagues found a significantly lower FEV1/FVC 
in their 5-year survivor group compared to those who died or received lung 
transplants [296]. Additionally, Schwartz et al. found decreased survival in IPF 
patients with higher FEV1/FVC [297]. Finally, Wells and co-workers developed a 
composite physiologic index for predicting survival in IPF in which the FEV1 is an 
important variable [298]. These studies indicate that first, airflow abnormalities are 
important in the pathogenesis of IPF and second, that routine clinical tests that 
measure both airflow and lung capacities can be used to assess disease severity 
and prognosis. 
These findings, along with the typical radiological features of traction 
bronchiectasis seen in IPF suggest that abnormalities in the airways and airflow 
are an important part of the pathogenesis in this disease [12]. Cherniack et. Al. 
showed that total lung capacity and FVC correlated the severity and extent of 
cellular infiltration of the alveolar walls [303]. Thus, any disease process that 
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affects both lung recoil and bronchial structure should impact both airflow and lung 
capacity simultaneously. Using the belief that fibrosis causes loss of total lung 
capacity and lung elasticity, we focused on the comparison between the standard 
FVC measure of disease progression in IPF to a new formula; FEV1/dFVC ratio = 
absolute value (FEV1 / (predicted FVC – actual FVC)). The goal of this research 
is to detect changes in disease progression and severity earlier in the disease 
course, enhancing clinical decision-making and decreasing the time to progression 





 The PANTHER trial yielded 264 patients for analysis. Patients were 
separated by whether their pulmonary fibrosis progressed over the course of the 
study (drop in 10% FVC) (Table 1). Descriptive statistics showed difference in 
FVC, FEV1 and DLCO % predicted values. Additionally, CPI and total lung 
capacity were different.  
The cohort of 85 patients (43 placebo/42 treatment) who achieved >10% 
decline in the FVC during the study were selected for FEV1/dFVC analysis (Figure 
43). Descriptive statistics compared placebo and treatment groups (Table 2). The 
average age of the patients was 67 years with 82% of patient’s being male. Over 




Figure 42. Comparing FEV1/dFVC ratio to FVC Alone 
Vicary et. Al., Unpublished 
 
We hypothesize that the FEV1/dFVC ratio will detect IPF progression earlier then 
FVC alone. Progression is marked by a decline of 10% from the patient’s baseline 
value. Using the belief that fibrosis causes loss of total lung capacity and lung 
elasticity, we compare the standard FVC measure of disease progression in IPF 
to FEV1/dFVC ratio to detect changes in disease progression and severity earlier 
in the disease course, enhancing clinical decision-making and decreasing the time 
to progression of end-points in clinical trials. 
 
FEV1/dFVC ratio = absolute value (FEV1 / (predicted FVC – actual FVC)) 



















Figure 43. PANTHER Trial Enrollment and Outcomes 
Vicary et. Al., Unpublished 
 
Patients with IPF between the ages of 35-85 years who had mild- to-
moderate lung-function impairment (defined as a forced vital capacity of ≥50% and 
a predicted carbon monoxide diffusing capacity of ≥30% were eligible. Patients 
had received the diagnosis of IPF on the basis of high-resolution computed 
tomography (CT) or biopsy 48 months or less before enrollment. The PANTHER 
trial database provided 240 patients for analysis. Individuals who achieved >10% 
decline in the FVC during the course of the study were selected for analysis; 42 
placebo and 43 treatment patients. No difference was detected in FVC between 
the placebo and treatment groups, so all 85 patients were included in statistical 
analysis. 
  
85 Patients >10% Drop in FVC
264 Eligible Patients
42 Placebo 43 Treatment
85 Patients for Analysis
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Table 1. Drop in 10% FVC Patient Cohort Baseline Characteristics 
Vicary et. Al., Unpublished 
The PANTHER trial patients were separated by whether their idiopathic pulmonary 
fibrosis (IPF) progressed over the course of the study (drop in 10% FVC). 
Differences in FVC, FEV1 and DLCO % predicted values were detected. 
Additionally, CPI and total lung capacity showed statistical differences. CT = 
Computer Tomography, FEV1 = Forced Expiratory Volume in One Second, FVC 
= Forced Vital Capacity, DLCO = Diffusing Capacity of the Lungs for Carbon 
Monoxide, CPI = Composite Physiologic Index   
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Table 2. FEV1/dFVC Ratio Patient Cohort Baseline Characteristics 
Vicary et. Al., Unpublished 
 
The cohort of 85 idiopathic pulmonary fibrosis (IPF) patients who achieved >10% 
decline in the FVC during the study were compared for baseline characteristics in 
placebo versus treatment group. No significant differences were detected between 
the placebo and treatment groups. CT = Computer Tomography, FEV1 = Forced 
Expiratory Volume in One Second, FVC = Forced Vital Capacity, DLCO = Diffusing 
Capacity of the Lungs for Carbon Monoxide, CPI = Composite Physiologic Index   
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Spirometry Value Distribution  
The patient cohort displayed Gaussian distribution for baseline values of 
FEV1, FVC and FEV1/FVC ratio (Figure 44). Baseline values included an average 
FEV1 of 2.3 liters (L) (73.7% predicted), average FVC of 3 liters (68%  
predicted) and an average %FEV1/FVC of 77.26%. Average baseline value of 
FEV1/dFVC was 2.6 with two outliers skewing the histogram (one with ~600, 
another with ~93). By nature of the formula, it is possible for very high numbers to 




 Time to 10% decline in FVC was compared to 10% decline in FEV1/dFVC. 
FEV1/dFVC detected a 10% decline significantly earlier then FVC alone (Table 3) 
(Stuart-Maxwell Test X2(3) = 23.58, p<0.001). The time to 10% decline in FVC was 
compared to 10% drop in FEV1/dFVC (Figure 45). 42.5% of the patients had a 
10% drop detected in FVC and FEV1/dFVC at the same visit. 25% of patients were 
detected 15 weeks earlier, while another 25% of the patients were detected 30 
weeks earlier. Cumulatively, over 50% of the patients had a 10% drop in 
FEV1/dFVC detected at least 15 weeks (1 visit) earlier.  
 
Secondary Outcomes 
 Investigating the potential role of spirometry values on clinical outcomes, a 
drop in 10% FVC and FEV1/dFVC ratio were analyzed as predictors for re-
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hospitalization and death. An increase in deaths was detected in the cohort who 
dropped more than 10% in their FVC (Table 4). No differences found between 
control and treatment cohorts using the FEV1/dFVC ratio were found (Table 5). 
Additionally, Kaplan-Meier comparison curves were computed for 
death/hospitalization using FVC alone or FEV1/dFVC, but neither showed enough 
efficacy to be used clinically (Figure 46). Lastly, patients were compared weekly 
for placebo vs treatment or those who had a %FVC drop at the same time as % 










Figure 44. Distribution of FEV1, FVC, FEV1/FVC and FEV1/dFVC Values 
Vicary et. Al., Unpublished 
 
The FEV1/dFVC patient cohort displayed Gaussian distribution for baseline values 
of FEV1, FVC and FEV1/FVC ratio. (A) Baseline values included an average FEV1 
of 2.3 liters (L) (73.7% predicted) with a range from 1-5 L. (B and C) Patients had 
an average FVC of 3 liters (68% predicted) with a range of 1-5 L and an average 
%FEV1/FVC of 77.26%. (D) Average baseline value of FEV1/dFVC was 2.6 with 
two outliers skewing the histogram (one with ~600, another with ~93).  
  





































































































































































































Table 3. FEV1/dFVC Ratio Decreases by 10% Earlier Then FVC Alone 
Vicary et. Al., Unpublished 
 
Time to 10% decline in FVC was compared to 10% decline in FEV1/dFVC. 
FEV1/dFVC detected a 10% decline significantly earlier then FVC alone (Stuart-
Maxwell Test X2(3) = 23.58, p<0.001).  
  
OVERALL















15 weeks 30 weeks 45 weeks 60 weeks Row Total
15 weeks 17 12 16 7 52
30 weeks 0 7 7 5 19
45 weeks 0 0 9 2 11
60 weeks 0 0 0 3 3
Column 



























Figure 45. FEV1/dFVC Earlier Detection in Patients by Weeks 
Vicary et. Al., Unpublished 
 
The time to 10% decline in FVC was compared to the time of 10% drop in 
FEV1/dFVC. Over 75% of patients had a 10% decline detected in FEV1/dFVC by 
30 weeks (3 visits), where a 10% drop in FVC had been detected in less than 50% 




























Table 4. Drop in 10% FVC as Predictor of Hospitalization/Death 
Vicary et. Al., Unpublished 
 
The PANTHER trial patients were separated by whether their pulmonary fibrosis 
progressed over the course of the study (drop in 10% FVC). Predicting re-
hospitalization and death endpoints showed a significant difference in deaths 





Table 5. FEV1/dFVC Ratio as Predictor of Hospitalization/Death 
Vicary et. Al., Unpublished 
 
The cohort of 85 patients who achieved >10% decline in the FVC during the course 
of the study were compared for endpoint characteristics in placebo versus 
treatment group. Predicting re-hospitalization and death endpoints showed no 
difference between FEV1/dFVC ratio and FVC.  
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Figure 46. Death and Hospitalization Receiver Operating Characteristics 
(ROC) Curve of FEV1/dFVC and FVC Alone 
Vicary et. Al., Unpublished 
 
Receiver operating characteristics (ROC) curves compare the FEV1/dFVC ratio 
versus FVC alone in regards to sensitivity and specificity as a predictor of death 
and re-hospitalization. FEV1/dFVC ratio and FVC alone showed no difference and 
neither were accurate enough predicting death and hospitalizations to be used 
clinically.   
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Figure 47. Patient Hospitalization/Death by Weeks 
Vicary et. Al., Unpublished 
 
(A) Using FEV1/dFVC ratio, there was no difference in survival detected between 
treatment and placebo groups. (B) No difference in survival between 10% drop in 
FVC and FEV1/dFVC detected at the same visit or FEV1/dFVC detected earlier 
were detected.  
Weeks
FVC 10% drop same time













































































With IPF affecting so many people around the world and having an average 
survival rate of 3 years, the need for better treatments is imperative. The FDA 
recently approved two drugs for the treatment of IPF and several other drugs are 
in development [287, 288]. Creating more sensitive markers for IPF progression 
can allow drug trials to be completed earlier, allowing for more efficient FDA 
approval. Better disease markers will also allow physicians to determine the best 
treatment regimen for patients.  
The current paradigm on the progression of pulmonary fibrosis has always 
included loss of lung volume due to loss of lung elasticity due to the expansion of 
fibrotic foci, but restrictive airway remodeling has been overlooked. The research 
presented here and by others show that including restrictive airway measurements 
might increase the specificity and sensitivity of spirometry as a diagnostic marker 
for fibrosis progression and survival. Nishiyama et. Al. showed lower FEV1/FVC 
(below 83%) was associated with increased patient survival [294]. Additionally, 
shown here, restrictive airway (FEV1) with lung volume (FVC) allowed for earlier 
detection of 10% decline then FVC alone.  
There are limitations to this study. Co-morbidities may affect the ratio, such 
as combined pulmonary fibrosis and emphysema diagnoses which showed to 
lower the FEV1/FVC ratio [304]. Additionally, only progressive patients (drop >10% 
FVC) were used for analysis. Including non-progressive patients would not have 
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allow us to compared our primary endpoints (FEV1/dFVC and FVC) for patients 
that did not drop 10% in FVC by the end of the study.  
Multiple values and tests may end up being used in clinical practice for 
measuring progression, including spirometry and biomarkers [305]. Daily FVC 
values recently showed significance in predicting patient survival [292]. 
Additionally, the 6-minute walk test (6MWT) has shown to be associated with 
dyspnea and quality of life scores, but no significant difference was detected 
between 6MWT and FVC [290]. We hope research presented here will help to 








 Pulmonary fibrosis is characterized by the accumulation of fibroblasts and 
the unrestrained chaotic expression and deposition of connective tissue matrices 
leading to effacement of the pulmonary architecture with loss of lung function. 
Environmental factors (e.g. asbestos and silica exposure), genetic factors (e.g. 
surfactant-related proteins and telomerase), and viral factors (herpesvirus) have 
been associated with the development of lung fibrosis, while other factors are 
believed to contribute to its progression (e.g., allergens, tobacco) [1, 13-17]. 
However, pulmonary fibrosis often occurs in subjects where a cause cannot be 
identified [1].   
Despite the growing association of genetics with pulmonary fibrosis, the 
mechanisms by which abnormalities in these genes lead to alterations in cellular 
functions; extracellular matrix expression, deposition and degradation; production 
of profibrotic growth factors; and, ultimately, disruption of lung homeostasis and 
pulmonary fibrosis remain poorly understood.  
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One genetic disorder associated with highly penetrant pulmonary fibrosis is 
the Hermansky-Pudlak Syndrome (HPS), a rare autosomal recessive disorder 
characterized by oculocutaneous albinism, bleeding diathesis, granulomatous 
colitis, and, in many cases, pulmonary fibrosis. HPS affects approximately 
1:500,000-1,000,000 people worldwide, and has been reported in individuals from 
India, Japan, China, United Kingdom, Western Europe, Pakistan, Canada and the 
United States [306, 307]; the HPS Network registry also includes patients from 
Israel, Australia, Hungary, Mexico, Brazil, Peru, Qatar, and Bolivia, among others. 
Although HPS is a very rare disease, it is relatively common in Puerto Rico, where 
the prevalence of HPS-1 is estimated to be about 1:1,800 in the Northwest region 
of the island, accounting for approximately 50% of all cases globally [308]. 
Unfortunately, the average life expectancy of HPS patients is 40-50 years and 
there are currently no effective treatments, with over 70% of patients dying due to 
complications directly related to the disease [309]. 
 Here, we summarize the current understanding of the pathogenesis of HPS 
and its clinical manifestations and management, while discussing recent 
discoveries that might lead to the identification of potential targets for intervention 
and effective therapies in the future. This review is intended to raise awareness 
about pulmonary fibrosis in HPS, and prompt interest in further research in this 
syndrome, research that could also hold the key for understanding more common 




7.2 Genetic and Functional Abnormalities in Hermansky-Pudlak Syndrome 
(HPS)  
 
HPS was first described in 1959 by Dr. Frantisek Hermansky and Dr. Paulus 
Pudlak who identified two patients with oculocutaneous albinism and bleeding 
diathesis in Czechoslovakia [310]. HPS is a non-sex-linked autosomal recessive 
disorder with no known disease manifestations in carriers. Ten types of HPS have 
been defined by nine unique genes distinguished by their signs, symptoms, and 
genetic cause; and in most cases, each subtype has more than one variant (Table 
6) [307, 311-313]. HPS-1 is the most common and generally severe subtype. HPS-
2 and -4 also have severe manifestations and HPS-10 has neurological changes, 
while patients with the other variants (HPS-3, 5-9) generally manifest somewhat 
milder symptoms [314]. 
In Puerto Rico, HPS-1 and -3 are the most common subtypes. This is 
because certain populations in Puerto Rico were established by a very small 
number of individuals who carried the silent gene (founder effect) [308]. One in 
twenty-one Puerto Ricans in the Northwest of the Island are carriers of the gene 
mutation (>160,000 people) [315]. Thus, it is estimated that 7–8 children with HPS 
will be born on the island each year [308]. In Puerto Rico, HPS-1 arises mainly due 
to a duplication/frameshift (16-base pairs) on exon 15 of the HPS1 gene, 
accounting for 45% of all HPS cases globally and most cases in the island [308, 
316]. Outside of Puerto Rico, HPS-1 is caused by different mutations within the 











HPS1 HPS1 NM_000195 10q24.2 BLOC-3 
HPS2 AP3B1 NM_003664 5q14.1 AP-3 
HPS3 HPS3 NM_032383 3q24 BLOC-2 
HPS4 HPS4 NM_022081 22q12.1 BLOC-3 
HPS5 HPS5 NM_0181507 11p15.1 BLOC-2 
HPS6 HPS6 NM_024747 10q24.32 BLOC-2 
HPS7 DTNBP1 NM_032122 6p22.3 BLOC-1 
HPS8 BLOC1S3 NM_212550 19q13.32 BLOC-1 
HPS9 BLOC1S6 NM_012388 15q21.1 BLOC-1 
HPS10 AP3D1 NM_003938 19p13.3 AP-3 
Table 6. Human Hermansky-Pudlak Syndrome (HPS) Variants 
Vicary et. Al., 2016 
 
HPS is a non-sex-linked autosomal recessive disorder with no known disease 
manifestations in carriers. Nine types of HPS have been defined by nine unique 
genes distinguished by their signs, symptoms, and genetic cause.  
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deletion (3,904-base pairs) in HPS3. HPS3 is believed to have developed in the 
1880-1890s in the central mountainous region of Puerto Rico [308, 316, 318]. 
Consistent with the genetic drift expected over hundreds of years, more recent 
studies have suggested that carrier frequencies for HPS1 and HPS3 are similar 
across Puerto Rico [308, 319].  
Exactly how the genetic mutations in HPS genes lead to all manifestations 
of the disease is unknown. HPS genes code for HPS proteins, which form 
complexes termed biogenesis of lysosome-related organelles complexes (BLOCs) 
(Figure 48) [320-322]. Lysosome related organelles (LROs) perform specialized 
functions in the sorting and trafficking of specific cargo. BLOC-3, a complex which 
includes the HPS1 and HPS4 proteins and others, functions as a Rab32/38 
guanine nucleotide exchange factor; these are proteins capable of activating small 
GTPases, thereby affecting intracellular signaling and downstream targets.  
HPS mutations impair the biogenesis and function of LROs, which explains 
some disease manifestations. For example, LRO dysfunction affecting pigment-
producing cells (termed melanocytes) is responsible for albinism. Specifically, in 
melanocytes, activated Rab32/38 is needed for the transport of tyrosinase and 
tyrosinase related protein 1 (TYRP1) from early ribosomes to melanosomes; this 
likely represents a key step and its disruption has been shown to lead to the 
oculocutaneous manifestations of HPS-1 [323]. In over 80% of patients with HPS, 
this is manifested by lentigines, while a small percentage of patients may also 
develop solar keratosis, squamous cell, or basal cell carcinomas [315]. Decreased 
pigmentation in the eyes causes legal blindness in most patients, as well as  
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Figure 48. Lysosomal-Related Organelles (LROs) in HPS 
Vicary et. Al., 2016 
 
Lysosome-related organelles (LROs) are a group of cell type-specific subcellular 
compartments that share some features with endosomes and lysosome, but also 
develop unique properties as they harbor specialized cargoes. Many of the clinical 
manifestations of HPS are explained by abnormalities in the formation and 
trafficking of LROs, including albinism (melanosomes), bleeding (platelet dense 
granules), and pulmonary fibrosis (likely related at least in part to abnormal 










photophobia, impaired dark adaptation, and nystagmus.  
Similarly, defects in platelet LROs leads to bleeding diathesis due to 
inhibition of the formation of platelet dense bodies [324]. In type II alveolar 
epithelial cells of the lung, Rab38 helps maintain lamellar body morphology and 
surfactant homeostasis [323]. The role of this defect in the development of 
pulmonary fibrosis is not known, but it is intriguing to note that abnormalities in 
surfactant proteins have been identified in idiopathic pulmonary fibrosis and related 
interstitial lung disorders [323, 325, 326]. Disease mechanisms remain uncertain 
for the occurrence of granulomatous colitis that has also been reported in 
approximately 15% of HPS patients, not necessarily tracking with occurrence of 
subtype risk for pulmonary fibrosis.  
Accumulation of an amorphous lipid-protein complex, ceroids, which 
increases with age in patients with HPS has been speculated to be a potential 
trigger for the development of tissue inflammation, possibly contributing to some 
of the multi-organ manifestations of HPS [315, 322, 327, 328].  
 
7.3 HPS and Pulmonary Fibrosis (HPS-PF) 
 
In a joint statement of the American Thoracic Society and European 
Respiratory Society, HPS-related pulmonary fibrosis (HPS-PF) and idiopathic 
pulmonary fibrosis (IPF) are considered similar entities (albeit with distinct causes) 
since both can show similar histological patterns [41]. IPF occurs spontaneously 
in most patients, but research has uncovered some genetic mutations in surfactant 
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proteins, mucins, and telomerases that are considered relevant [1, 14-17]. Only 
HPS-1, -2 and -4 are associated with the development of pulmonary fibrosis, but 
100% of HPS-1 patients will develop HPS-PF [328]. Both HPS-PF and IPF are 
characterized by irreversible and progressive fibrosis of the lung parenchyma and 
interalveolar septa, ultimately leading to death from respiratory failure. Similar 
symptoms are found in HPS-PF and IPF, including increased dyspnea initially 
manifested as exercise intolerance that progresses to dyspnea at rest and the 
need for supplemental oxygen over time.  
One intriguing, but important difference between IPF and HPS-PF is the age 
at which pulmonary fibrosis is detected. Spontaneous IPF manifests in patients 
mostly over age 50 (this is not the case for familial IPF), while HPS-PF occurs 
much earlier (30-40 years). Another major difference is that the average survival 
time after diagnosis differs with IPF carrying a dismal 3-year survival rate of 50%, 
while HPS patients live approximately 10 years after diagnosis [5, 329]; this might 
reflect earlier ascertainment and not differing natural history.   
Current understanding of the pathogenesis of pulmonary fibrosis points to 
epithelial cell dysfunction as the inciting cause of the disease. Several intracellular 
trafficking processes might be affected leading to endoplasmic reticulum stress 
and apoptosis caused by environmental exposure to injurious agents (e.g., viral 
infection, recurrent aspiration of gastric contents) or through genetic abnormalities 
(e.g., surfactant proteins). Injured or dysfunctional epithelial cells are proposed to 
promote the accumulation of fibroblasts that are responsible for the excessive 
deposition of extracellular matrices [18]. The origins of these fibroblasts are 
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unclear, but combinations of mechanisms are hypothesized, including the 
transdifferentiation of epithelial cells (epithelial-mesenchymal transformation), the 
differentiation of fibrocytes and stem cells, and the proliferation of resident 
fibroblasts [42].  Regardless of their source of origin, the interplay between 
dysfunctional epithelial cells and activated fibroblasts (also termed myofibroblasts 
because of their expression of smooth muscle cell markers) seems to drive 
unrestrained collagen deposition and tissue scarring.  Underlying amplifying 
factors like aging and epigenetic changes are thought to further perpetuate the 
progressive nature of pulmonary fibrosis [18]. 
There is a growing body of work dissecting the mechanisms of pulmonary 
fibrosis in HPS.  HPS gene products are ubiquitously expressed and thus many 
cell types have been potentially implicated as contributors to the pathogenesis of 
HPS-PF. First, there is strong evidence that macrophage-mediated inflammation 
precedes pulmonary fibrosis in HPS patients. Bronchoalveolar lavage (BAL) fluid 
of HPS-PF patients contained increased total cell counts and alveolar 
macrophages [330], at a time when patients still had relatively preserved lung 
function. Furthermore, alveolar macrophages from HPS patients have been shown 
to be constitutively activated, expressing excess cytokines and chemokines when 
studied ex vivo [330]. BAL fluid from HPS patients also had elevated levels of 
several cytokines, including chemokine (C-C motif) ligand 2 (CCL2/MCP-1), 
macrophage colony-stimulating factor (M-CSF), and granulocyte-macrophage 
colony-stimulating factor (GM-CSF) [330].  Interestingly, elevation of CCL2 levels 
was directly associated with the progression of HPS-PF; a similar association has 
	 137	
been observed in IPF and animal models of pulmonary fibrosis [331, 332]. 
Abnormalities in fibroblasts have also been reported including increased 
expression of galectin-3, a β-galactoside-binding lectin with profibrotic effects 
[333].  In addition, patients with HPS-PF have been found to have increased 
numbers of circulating CXCR4-positive fibrocytes compared to subjects with HPS 
without lung disease or healthy control subjects [334]. Increasingly, as suggested 
for IPF, studies point to the type II alveolar epithelial cell as central in the 
pathogenesis of HPS pulmonary fibrosis. Lamellar bodies (responsible for 
producing surfactant proteins) are a type of LRO [326], making alveolar epithelial 
cells a good candidate for dysfunction in HPS.   
As HPS lung tissue is limited in availability for research due to disease rarity 
and contraindication to lung biopsy because of the bleeding diathesis, much HPS 
research to date has been conducted in murine models, which also afford 
opportunities for access to cells and tissues, and genetic manipulations not 
possible in humans. Murine models of HPS reliably share many aspects of the 
human disease including hypopigmentation, deficiency of platelet dense granules, 
and abnormalities of type II alveolar epithelial cells and alveolar macrophages 
(Table 7 and Table 8).  Mice have more than 16 different genes with HPS-like 
phenotypes [335], though many of the gene functions are unknown. At least six 
mouse models have the orthologous mutations to the human genes [336-341].  
Interestingly, murine models of HPS-1 (Pale ear) and HPS-2 (Pearl) show 
activation of alveolar macrophages in the lung, but not in the blood or peritoneum 
[342, 343].  Pale ear HPS1 mice do not develop spontaneous fibrosis, but have  
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Mouse Model Mouse RefSeq Mouse Chromosome Location 
Pale Ear NM_019424 Chr19 
Pearl NM_009680 Chr13 
Cocoa NM_080634 Chr13 
Light Ear NM_138646 Chr5 
Ruby eye-2 AF534396 Chr7 
Ruby eye NM_176785 Chr19 
Sandy NM_025772 Chr13 
Zebrafish NM_001025476 Chr15 
Pallid NM_019788 Chr2 
Muted NM_139063 Chr13 
Cappuccino NM_133724 Chr5 
Mocha    NM_007460   Chr10 
Table 7. Mouse models of HPS 
Vicary et. Al., 2016 
 
There are several murine models of HPS. Each model of HPS has been defined 
by a unique gene and a name based off the specific characteristics. 
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Physiology/Cellular Abnormality Mouse HPS Gene(s) 
Hypopigmentation All 
Prolonged Bleeding All 
Lung Disease HPS1/HPS2 Double Mutant, 
Pldn 
Decreased Lysosomal Enzyme Secretion  Most 
Decreased CTL Granule Secretion Rab27a 
Dysregulated Mast Cell Granule Secretion HPS6 
CD1d Deficiency HPS2 
NK Cell Dysfunction HPS1, Pldn, rp 
Decreased Proplatelet Production Rabggta 
Night Blindness HPS2 
Susceptibility to Anesthetics Pldn, rp 
Protection from Atherosclerosis HPS4, HPS6 
Increased Emperipolesis Rabggta 
Otolith Deficiency Ap3d, Pldn, mu 
Hippocampal Granule Deficiency Ap3d 
Decreased Lifespan Rabggta, HPS2, HPS3, Pldn 
Table 8. Phenotype and cellular abnormalities in mouse models of HPS 
Vicary et. Al., 2016 
 
Murine models of HPS reliably share many aspects of the human disease including 
hypopigmentation, deficiency of platelet dense granules, and abnormalities of type 
II alveolar epithelial cells and alveolar macrophages.  
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higher baseline collagen deposition and show increased inflammation and 
collagen expression in response to silica challenge [342, 344, 345].  In response 
to bleomycin, HPS-1 and HPS-2 mice developed fibrosis significantly earlier and 
to a greater extent than wildtype mice [343].  Also, higher levels of transforming 
growth factor-β were detected in bleomycin-treated HPS mice.   However, it is 
intriguing that spontaneous lung fibrosis does not occur in these single mutant 
models, suggesting that other factors and secondary hits are required to develop 
the full manifestations of the disease. With aging, spontaneous fibrosis has been 
reported in a HPS double-mutant model, generated by mating HPS-1 and HPS-2 
mice [346].  Alveolar epithelial cell dysfunction in HPS remains under study, but 
recent publications implicate alveolar epithelial cell apoptosis [346, 347], 
Chitinase-3-like-1 and its receptors [348], and autophagy [349] as potential 
mechanisms.  Macrophage-mediated inflammation is also present in HPS mouse 
models.  However, murine bone marrow transplant studies have demonstrated that 
macrophage abnormalities and fibrotic susceptibility are likely due to epithelial 
dysfunction with type II alveolar cell death, not intrinsic macrophage defects [347]. 
This is important because it suggests that HPS-PF could be driven more than just 
macrophage mutations. Collectively, these studies indicate the role of HPS mice 
as an experimental model for HPS disease, and identify mechanisms that are likely 





7.4 Diagnosing HPS and HPS-PF 
 
The diagnosis of HPS includes the documentation of oculocutaneous 
albinism and platelet storage pool deficiency [328].  HPS patients are potentially 
identified shortly after birth by their albinism, though the degree of 
hypopigmentation is variable.  Other individuals are not diagnosed until after 
experiencing other disease complications such as excessive bleeding after 
circumcision or easy bruising; over 75% of patients have bruises at the time of 
clinical examination. Bleeding time is often quite prolonged, but is not 
recommended for diagnostic or screening due to poor specificity and lack of 
prognostic value [350]. Ophthalmologists might be the first to suggest testing for 
HPS due to diminished vision, with transillumination of the iris in addition to 
nystagmus and strabismus.  
Testing for HPS is currently limited by complexity, expense, and availability 
of specialized diagnostics required for confirmation. The gold standard test for the 
platelet abnormality in HPS is analysis by whole mount electron microscopy for the 
absence of dense bodies [351].  Testing of platelet aggregation following platelet 
stimulation with adenosine diphosphate or epinephrine (using a platelet 
aggregometer) [352] provides a less specific alternative. Genetic testing plays a 
growing role in diagnosis, and it is important for determining HPS subtype (and 
prognosis).  Such assessments are also essential to determine the numbers of 
individuals with distinct HPS subtypes in any given community.  However, genetic 
testing has not been widely implemented for HPS due to the cost of next-
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generation sequencing [353]. Genetic testing could be used to help identify specific 
mutations as the price of next-generation sequencing decreases. Not all patients 
with HPS have identified genetic mutations though, suggesting that there are 
additional HPS disease-causing genes to be discovered.  In the absence of genetic 
confirmation, patients with the classic manifestations of the syndrome (e.g., 
albinism with bleeding disorder, colitis or pulmonary fibrosis) should be considered 
to have HPS unless proven otherwise. 
The progression of HPS-PF is characterized by the development of 
dyspnea and increasingly debilitating hypoxia. Thus, it is recommended that all 
patients with HPS-1, -2, and -4 be evaluated for lung function during adolescence 
and yearly thereafter [328].  Pulmonary physiology is best evaluated with 
pulmonary function tests including diffusing capacity for carbon monoxide.  Early 
evidence of pulmonary fibrosis might be manifested by a decrease in force vital 
capacity and lung volumes (indicating a restrictive defect) and reduced diffusing 
capacity for carbon monoxide, which is typical of fibrosing lung disorders.  A six-
minute walk test (6MWT) using a portable oximeter should also be considered as 
hypoxemia may only be detected during exertion in early stages of the disease.   
HPS-PF is best evaluated by high-resolution computed tomography.  
Common changes include ground-glass opacities, reticulation of interstitial spaces 
and, with advanced disease, loss of lung volume, honey-combing, and traction 
bronchiectasis [314, 354, 355].  The predominant findings in HPS-PF occur within 
the lung periphery and progress towards the central portion of the lung as the 
disease progresses. The most common abnormalities in cases of minimal severity 
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are interlobular septal thickening, reticular opacities, ground-glass opacities and 
subpleural honey-combing. As the disease progresses, reticular opacities and 
subpleural honeycombing are present to a greater extent. Additionally, a wider 
range of findings including bronchiectasis, peribronchovascular thickening, and 
pleural thickening have been reported. In severe cases, sub-pleural honeycombing 
and bronchiectasis are more common, and subpleural reticular opacities, ground-
glass opacities, and peribronchovascular thickening are also present [322, 354, 
356]. Thus, although the pattern of pulmonary fibrosis in HPS-PF may be similar 
to that observed in IPF, several findings are not consistent such as ground glass 
opacification and pleural thickening (Figure 49). 
In contrast to cases being evaluated for IPF and related disorders, a lung 
biopsy is not recommended in suspected HPS-PF due to the bleeding diathesis.  
Imaging studies and pulmonary function tests could be conducted to track 
progression of fibrosis.  Bronchoscopy has been used for research purposes, but 
does not have proven benefits for HPS diagnosis.  In short, the diagnosis of HPS-
PF differs from that of IPF in that lung biopsy is not recommended, and a high level 
of suspicion is required at an early age in patients with HPS-1, -2 and -4. 
 
7.5 Treatment and Management of HPS-PF 
 
At the moment, no Federal Drug Agency (FDA) approved interventions are 
specifically designated for the treatment of HPS and HPS-PF, and progress in this  
	 144	
 
Figure 49. Examples of Chest CT findings in Subjects with HPS-PF 
Vicary et. Al., 2016 
 
 (A) Case of 50 years old patient with HPS-1 showing mild changes consistent of 
subpleural infiltrates. (B) Case of 41 years old patient with central infiltrates. (C) 
Ground glass opacification. (D) Case of 31 years old patient with mid to upper 
lung infiltrates (D).  The images used were from patients consented under the 
Rare Lung Diseases Consortium HPS study under Vanderbilt University IRB 





area has been hindered by the lack of large placebo-controlled, randomized clinical 
trials. Similar to IPF, corticosteroids have not shown clinical efficacy and are not 
recommended for HPS-PF.  Thus, until safe and effective treatment strategies are 
developed, lung transplantation may remain the only effective treatment [319, 354, 
357].   
As is the case for IPF, treatment relies on preventive care and support as 
needed. Patients with hypoxemia should be provided supplemental oxygen. 
Infection prophylaxis is also critical; thus, influenza and 13-valent and 23-valent 
pneumococcal vaccinations are recommended, and administered with caution to 
avoid intramuscular bleeding. Additionally, a 5 year polysaccharide booster 
vaccine may be beneficial [358]. Avoidance of cigarette smoke and other 
pulmonary irritants is critical, while daily exercise is recommended to avoid 
deconditioning.  HPS patients should avoid unprotected eye and skin exposure to 
the sun due to their albinism.  Menometrorrhagia is common in women, but can be 
lessened with medication [315, 328]. Further, patients with HPS should avoid 
aspirin and non-steroidal anti-inflammatory drugs due to platelet inhibition. 
Extensive injuries should prompt a hospital visit and consultation of a hematologist.   
The approval of two new anti-fibrotic drugs, pirfenidone and Nintedanib, for 
the treatment of IPF, has prompted new interest in identifying drugs capable of 
reversing or, at the very least, halting the progression of HPS-PF. It should be 
emphasized that these drugs are not curative, but instead appear to slow down the 
decline of lung fibrosis in IPF. Pirfenidone, a small molecule capable of inhibiting 
TGF-b, showed success in slowing pulmonary dysfunction in clinical trials with IPF 
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patients [50, 52]. Interestingly, ex vivo, pirfenidone showed significantly decreased 
inflammatory cytokines in HPS patient alveolar macrophages [330]. An initial 
clinical trial of HPS-1 patients with pirfenidone showed no significant slowing of 
fibrosis progression by forced vital capacity (FVC) [329]. Secondary analysis of 
this patient population showed patients with an initial FVC value >50% of expected 
had significant decrease in the progression of their pulmonary fibrosis. 
Disappointingly, a follow-up study with HPS-1 and -4 patients with milder disease 
showed no significant benefit and was stopped prematurely, but it was likely 
underpowered [359]. Future clinical studies will be needed in HPS to identify 
effective treatments.  
Considering the genetic basis for the development of HPS, one would 
predict that gene transfer might be successful in treating this disease. In fact, 
others have used lentiviruses for the transfer of the HPS1 gene into human dermal 
melanocytes in vitro and shown correction of the expression and function of the 
HPS1 gene in these cells [325]. However, difficulties in gene transfer methods in 
the lung, particularly to the alveolar epithelium, hamper progress in this area, and 
much still needs to be learned before gene therapy is considered for potential 
correction of BLOC-3 dysfunction. 
 
7.6 Summary and Discussion 
 
HPS is an autosomal recessive disorder caused by defects in the 
biogenesis of lysosome-related organelles (LROs) and intracellular trafficking.  
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Even though HPS is considered an orphan disease (affecting less than 200,000 
individuals in the U.S.), its consequences are devastating and often affect young 
individuals. The epidemiology, natural history, clinical heterogeneity, and best 
approach to pulmonary monitoring in this population remain insufficiently 
understood. Despite significant scientific advances, additional research is needed 
to identify the mechanisms by which the genetic mutations responsible for HPS 
result in the clinical manifestations of the syndrome. In vitro and ex vivo studies 
with tissue, cells, blood, bronchoalveolar lavage fluid and other samples collected 
from patients, as well as in vivo studies in animal models hold promise for 
determining relevant biological pathways for intervention. Well-conducted placebo 
controlled and randomized clinical trials will accelerate the evaluation of new anti-
fibrotic agents and other interventions with therapeutic potential. Undoubtedly, the 
small number of patients affected by HPS will make large-scale studies difficult. 
Currently, two clinical trials are recruiting HPS-PF patients to hopefully develop 
better biomarkers for disease progression (NCT02368340, NCT00001456). In the 
end, such investigations should lead to effective and safe therapies for HPS and 
its manifestations, especially pulmonary fibrosis. In the meantime, we must find 
ways to address the clinical needs of these patients. The diagnosis, management, 
and follow-up of these patients will require the establishment of multidisciplinary 
centers of excellence staffed with experts in this area. In Puerto Rico, the 
increased incidence of HPS warrants the development of such a center.  
Considering that centers with capabilities for lung transplantation are not available 
in Puerto Rico, connections with centers in the U.S. with transplantation capability 
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is important since this procedure is currently the only option for a significant 





SUMMARY AND DISCUSSION 
 
Pulmonary fibrosis affects millions worldwide. This condition is associated 
with excessive accumulation of activated fibroblasts and chaotic deposition of 
collagens and other extracellular matrices that lead to obliteration of the healthy 
lung structure. In many cases, this condition is progressive, thereby leading to lung 
dysfunction and, ultimately, respiratory failure and death. This is true for IPF, a 
stereotypical fibrosing lung disorder that affects over 100,000 patients in the U.S., 
and carries a poor prognosis, with an average survival limited to 3 years after 
diagnosis [1, 2]. Although two FDA-approved drugs have recently reached the 
market, they do not improve lung function and long term efficacy is uncertain [50, 
52, 54]. Thus, studies directed at better understanding the pathophysiology of this 
condition and its early detection are needed. 
Exactly how tobacco contributes to this condition is unknown. 
Understanding the pathogenesis of tobacco-related diseases is a significant public 
health problem, with approximately 40 million Americans smoking cigarettes. 
Tobacco smoke is thought to contribute to the development and progression of 
pulmonary fibrosis as many patients with IPF and related fibrosing lung disorders
	 150	
 are current or ex-smokers [1, 23-25]. This research focused on a major 
component of tobacco, nicotine, because of recent studies showing that, in 
addition to promoting addiction, nicotine may stimulate cell proliferation, affect 
redox reactions, influence inflammation, and promote tissue remodeling during 
embryogenesis. Thus, this dissertation set out to study if nicotine promotes ECM 
expression in pulmonary fibroblasts, the main effector cell in pulmonary fibrosis, 
and the mechanisms responsible for these effects; examine the impact of nicotine 
on injury-induced lung fibrosis; and determine if nicotine influences survival after 
injury. We also set out to test the prognostic impact of non-invasive measures 
capable of detecting early progression of fibrosis. Multiple in vitro and in vivo 
models as well as national databases were used to address these complex areas. 
We found that nicotine promotes the expression of fibronectin and type I 
collagen, ECM components highly expressed in injured tissues and implicated in 
wound healing and disrepair. Interestingly, we identified a7 nAChRs as the 
receptors responsible for these events. Based on the above, we predicted that 
nicotine would enhance fibrosis in a bleomycin-model of lung injury. Nicotine did 
enhance fibrosis in this model but, interestingly, it appeared to be both harmful and 
protective as higher doses of bleomycin increased mortality, yet nicotine reduced 
this harmful effect. The latter was mediated via a7 nAChRs as well. Finally, we 
defined a new formula obtained through lung physiological testing that may be 
useful in the clinical arena for early detection of progression of lung fibrosis. These 
findings are considered novel and important for the following reasons. 
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First, our data provide a mechanistic description that links tobacco exposure 
to the development of fibrosing lung disease. However, it is important to note that 
nicotine does not cause lung fibrosis. Instead, it promotes relative alterations in the 
composition of the ECM without altering the overall tissue architecture. This effect, 
termed transitional remodeling, may not create physiological abnormalities at 
baseline, but we speculate that it may render the host susceptible to disrepair after 
a second insult (e.g., infection or inhalation of toxicants). This is an intriguing 
concept as it suggests that other conditions might promote transitional remodeling. 
In fact, it has been reported that chronic alcohol abuse might lead to similar 
changes [360]. Of note, aging is also associated with transitional remodeling. This 
is highly relevant since aging is yet another factor linked to the development of IPF 
[361]. Thus, identifying challenges like nicotine, that can promote transitional 
remodeling would be important as these observations might allow us to identify 
those which are susceptible to pulmonary fibrosis after injury. Of course, genetics, 
extent of injury, nature of the insult, and other factors are likely to contribute, and 
this explains why not all smokers develop pulmonary fibrosis. 
The concept of transitional remodeling is also important because it raises 
questions as to how this process may promote disrepair. Our work shows that 
monocytic cells cultured atop of ECMs derived from nicotine-treated lung 
fibroblasts express high levels of the pro-inflammatory cytokine IL-1b. Thus, we 
speculate that chronic nicotine exposure might promote transitional remodeling 
that does not cause disease at baseline, but may promote disrepair after injury by 
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stimulating excessive inflammation induced through its interaction with immune 
cells recruited to the lung after a second insult (Figure 4).   
Exposure to tobacco smoke is historically pro-inflammatory, exposing the 
lung to thousands of compounds and heat. Conversely, nicotine alone is typically 
considered anti-inflammatory with activation of the cholinergic anti-inflammatory 
pathway [362]. This belief is conflicted by others demonstrating nicotine can 
contribute to disease by stimulation of inflammation [363]. Together, the role of 
nicotine is still being investigated, but the differential effects of nicotine on 
inflammation may depend on dosage, organ and cells exposed. This is supported 
by the presence of a7 nAChRs present on several different cell types present 
throughout the body. Thus, nicotine may directly reduce inflammatory processes 
in immune cells, but the production of transitional matrices indirectly induces 
inflammation. At baseline, the anti-inflammatory effects of nicotine might be helpful 
to avoid disrepair, but this might render the host susceptible to infection. On the 
other hand, nicotine’s pro-inflammatory effects might be helpful to combat 
infection, while promote disrepair and tissue fibrosis. Fine tuning of these 
processes will be required to target cholinergic signaling in ways that promote 
healthy rather than a fibrotic lung state. 
This work also suggests that the newly deposited transitional matrix may 
affect other pulmonary cells involved in the reparative process such as epithelial 
cells, lung fibroblasts, and endothelial cells. We speculate that by altering the 
underlying ECM, the injured lung is less able to return to its original structure after 
injury. If true, preventing the development of a transitional matrix might be 
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therapeutic. On the other hand, it is conceivable that transitional matrices are 
necessary for adequate repair after certain (and perhaps less devastating) insults. 
Thus, further investigations are needed to determine the true role of transitional 
matrices prior to engaging in work directed at targeting this process in the clinical 
arena. Nevertheless, our work provides a model and a framework on which to 
design such studies. 
Additionally, an important aspect of the concept of transitional remodeling 
is whether it affects the lung at baseline in ways that promote disrepair other than 
via inflammation. We hypothesized that perhaps nicotine-induced transitional 
remodeling may affect tissue stiffness. The latter is important when considered 
against emerging literature suggesting a role for mechanobiology in the control of 
biological functions. In the lung, one can envision cells embedded in a normal ECM 
with a certain stiffness that allows for careful regulation of cellular signaling. This 
is disrupted in fibrosis where tissue stiffness is greatly enhanced, thereby 
promoting differentiation, fibroproliferation and further ECM overexpression.  
However, we do not know if nicotine-induced transitional remodeling influences 
tissue stiffness. We predict that nicotine-induced transitional remodeling may only 
enhance tissue stiffness slightly, but by promoting disrepair and enhanced fibrosis, 
it might lead to significant alterations in tissue stiffness after a second insult. We 
set out to study this using atomic force microscopy and found increases in lung 
tissue stiffness in animals exposed to both bleomycin and nicotine when compared 
to those treated with bleomycin alone. These preliminary data needed to be 
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confirmed and further investigations will be required to determine the true impact 
of transitional remodeling on lung tissue stiffness. 
Another important observation made by this work relates to a7 nAChRs, as 
these receptors mediated the effects of nicotine in our in vitro and in vivo models. 
This is important for two main reasons. First, there are at least 13 nAChRs that 
could be targeted, but our studies point to a7 nAChRs, thereby accelerating this 
research significantly. Also important is the fact that there are currently clinically 
available FDA-approved agents capable of targeting these receptors (e.g., 
Varenicline) and others in development (PNU-282987). Therefore, technology is 
already available to develop safe and effective methods of targeting these 
receptors if further data confirm that a7 nAChRs are indeed worth targeting for 
intervention in fibrosing lung disorders.  However, it should be highlighted that a7 
nAChRs are present in nearly all cells, ranging from neuronal cells to pulmonary 
cells. Thus, targeting this receptor might create problems as other organs are 
affected (e.g., brain). Also, how a7 nAChRs modulate intracellular signaling in the 
presence of other nAChRs is not entirely clear. Additionally, our data suggest that 
absence of a7 nAChRs has unforeseen effects at homeostasis. One explanation 
is that its elimination might unveil the roles of other nAChRs which may or may not 
be protective in the setting of injury and disrepair. The cholinergic signaling system 
is quite complex and further information will be required before these findings could 
be exploited at the clinic. 
Despite the above, our studies strongly suggest that chronic nicotine 
exposure promotes lung tissue remodeling and may enhance inflammation, 
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thereby promoting disrepair after injury and fibrosis. Thus, avoidance of tobacco 
exposure is important. However, we also found that nicotine has some protective 
effects. In our hands, and as observed by others, higher doses of bleomycin 
induced mortality. However, nicotine was protective in this setting and this effect 
was again mediated via a7 nAChRs. Thus, like a coin, nicotine appears to have 
two faces. On one hand, nicotine can promote disrepair after injury, whereas on 
the other hand, it can promote survival. This is important as one would need to 
dissect these distinct effects to take advantage of the beneficial ones, while 
reducing the injurious ones.  In our model, we found that nicotine was associated 
with alterations in cytokine expression, but other than significant changes in IL-1b, 
little was found that could explain the observations made. However, we did 
observe an upregulation of superoxide dismutase expression and activity in the 
lungs of nicotine-treated animals, and these effects was eliminated in the a7 
nAChRs knockout mice. Thus, increased anti-oxidant activity through expression 
of SOD might explain the beneficial effects of nicotine on injury-induced death, but 
this will require further investigation. Even more convoluting is the fact that recent 
data suggest that anti-oxidants might benefit some patients with IPF, while not 
having an effect and even worsening outcomes in many others [364, 365]. These 
effects are related to genetic variants that influence responsiveness to these 
agents (e.g., TOLLIP) [366]. Our data suggests that in patients with such genetic 
variants, nicotine might be protective, while it might be detrimental in others.  
Further research linking these events to genetic variants will be required before we 
can determine the true role of nicotine in fibrosing lung disorders and death. 
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Together, our studies help explain the role of smoking in fibrosing lung 
disorders, unveil a7 nAChRs as potential targets for intervention, further define the 
concept of transitional remodeling, its impact, and reveal how chronic nicotine 
exposure might influence multiple systems in ways that promote tissue remodeling.  
However, this work would not be useful if this new knowledge cannot be translated 
to the clinical arena. To that end, we began to examine ways to detect early 
progression of fibrosis. For this, we moved from bench work and animal models to 
human data.  This retrospective analysis revealed that a new formula based on 
variables obtained via regular physiological testing might detect early progression 
of fibrosis. This is important for clinical research as many studies evaluating the 
impact of novel interventions in lung fibrosis require a significant number of 
patients and at least 52 weeks. This explains why these studies typically require a 
multi-center approach and tens of millions of dollars for completion.  However, 
novel approaches capable of identifying disease progression earlier would 
potentially decrease the number of subjects required as well as the time needed 
to reach a statistically meaningful result. Based on our data, we speculate that the 
IMPULSIS and CAPACITY studies, which helped bring the two new anti-fibrotic 
drugs to the market, could have been terminated much earlier, perhaps 3-6 months 
earlier, thereby decreasing expenses by at least a third. More importantly, this 
approach would be extremely helpful at the clinic as clinicians could identify 
patients not responding to a particular intervention earlier without the need for 
radiologic testing and larger waiting periods.  
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One interesting aspect of the new formula is that it predicted early 
progression based on the drop of physiological function, but it failed to predict 
hospitalization and acute exacerbations. This suggests that deterioration of lung 
function is not directly correlated to those other variables of patient outcomes. 
Based on these observations, this new formula will need to be tested for several 
variables prospectively to determine its true sensitivity and specificity.  
In summary, this work provides a foundation for further research directed at 
defining the true role of tobacco and how interventions targeting the cholinergic 





Figure 50. Dissertation Summary 
Vicary et. Al., Unpublished 
 
Nicotine induces a transitional matrix consisting of increased collagen type I, 
fibronectin, and a-SMA expression through a7 nAChRs. This transitional matrix 
renders a host susceptible to accelerated pulmonary fibrosis exposed to lung 
injury. Alternatively, nicotine induces the anti-oxidant, SOD 1, which appear to 
protect against mortality induced by bleomycin-induced lung injury. The promotion 
of both remodeling and anti-oxidants is an intriguing idea, because it suggests that 
activation of nAChR might decrease oxidative stress, while increasing tissue 
remodeling. This interaction may be critical to the pathogenesis of chronic lung 
disorders like pulmonary fibrosis characterized by ECM remodeling with low levels 
of inflammation. Lastly, including a measure of obstructive airway in the 
FEV1/dFVC ratio for measuring IPF progression allows the earlier detection of 




















There were several strengths of this dissertation. One strength is the 
identification of a transitional matrix as a new potential mechanism mediating 
interaction between pulmonary fibrosis and environmental toxicants (i.e., nicotine). 
This work describes a characterization of one in vitro and two murine models of 
lung injury (acute lung injury and pulmonary fibrosis) after chronic nicotine 
exposure. Characterization of these models using a7 nAChR knockout cells and 
mice allows for a better understanding of how nicotine-a7 nAChR interaction 
affects the lung prior to and after exposure to a secondary injury. The findings of 
this study provide rationale to investigate a7 nAChR as a therapeutic target for 
clinical treatment, especially with drugs currently in development and FDA 
approved (e.g. varenicline and PNU-282987). 
 Additionally, development and verification of lung decellularization 
methodology allows for the investigation of the mechanical properties and integrin 
interactions of the lung. Pulmonary fibrosis is marked by pulmonary dysfunction, 
which can be further investigated using acellular lungs. Understanding differences 
in extracellular matrix composition induced by a pulmonary challenge can provide 
new therapeutic targets separate from cells. 
 Lastly, clinically tracking the progression of pulmonary fibrosis is critical in 
patient care and clinical trials. Developing a new non-invasive measure of fibrosis 
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progression allows for improved patient care and shorter clinical trials, save 




Although several models and approaches were used in this dissertation, it 
should be emphasized that most of the studies were based on in vitro and animal 
models of lung disease. The model of bleomycin-induced fibrosis is the most 
commonly used murine model to investigate pulmonary fibrosis, but it does not 
fully capitulate the human disease. The model does not reflect the idiopathic nature 
of IPF and given time, bleomycin-induced fibrosis will naturally resolve.  
Furthermore, this dissertation focuses on nicotine, one of several thousand 
compounds in cigarette smoke. Utilizing nicotine alone, allowed investigation of 
specific cellular mechanisms and pathways, but lacks the interactions seen in the 
complex chemical composition of cigarette smoke. Additionally, nicotine was 
administered via the oral route rather than via inhalation. When inhaled, nicotine 
concentrates in the lung before distributing through the bloodstream. This 
characteristic was not mimicked by the oral administration used in this dissertation. 
Thus, it is not certain if our findings are generalizable to models of smoke inhalation 
or if they are relevant to humans. Currently, lungs-on-a-chip systems are being 
developed, which will allow for better investigations of the effects of tobacco smoke 
on pulmonary cells [367]. In contrast, they might be quite important considering the 
emergence of e-cigarettes in younger adults.  
	 161	
Lastly, despite showing that FEV1/dFVC detected earlier pulmonary decline 
when compared to FVC alone, specificity still needs to be verified. This will involve 
utilizing CT scans to verify patient loss of FEV1/dFVC is associated with increased 
pulmonary fibrosis. This work may end up requiring an increase or decrease in the 
10% threshold to be prognostically accurate. 
The different approaches used in this dissertation provide a variety of 
weaknesses, but together, these can be addressed through future research and 




Pathway of Nicotine Protection 
 
Although this dissertation shows the involvement of a7 nAChRs and Erk, 
the pathways by which nicotine induces collagen type I and fibronectin are not 
completely elucidated. Whether the same pathway also controls the nicotine 
induction of SOD1 is unknown. Additionally, the potential involvement of nicotine 
as well as SOD2 and SOD3 need to be investigated. Finding additional pathway 
mediators will be important, including potentially, Nrf2. Knockout and 
overexpressing mice for the three SODs are available, providing useful tools to 
further investigate the role of SODs in acute lung injury.  
 
Integrin Induction of IL-1b 
 
 Showing a transitional matrix can induce IL-1b expression through a2 
integrin activation is intriguing concept. Investigating this mechanism of 
inflammation activation could provide druggable targets. Excessive inflammasome 
activation has been associated with neurogenerative and metabolic diseases, but 
recent research has also implicated inflammasomes in pulmonary fibrosis [368, 
369]. Inflammasome activation drives cleavage of IL-1b to its active, pro-
inflammatory, form. Some research has implicated integrins in the activation with 
inflammation. In a murine model of arthritis, blockade of a2b1 integrin decreased 
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inflammation and the number of Th17 cells [370, 371]. Additionally, another murine 
model of rheumatoid arthritis, knockout of a2b1 integrin reduced basal levels and 
blocked TNF-a induction of ERK-1/2 [372]. In airway smooth muscle cells, a2b1 
integrin activation mediated IL-1b-dependent secretory responses [373]. Lastly, 
a2b1 is not the only integrin worth investigation, with inhibition of the a5b1 integrin 




Another form of oxidant stress is best known as redox stress and can be 
measured by evaluating redox potential [375]. Redox stress is created by the 
relative concentrations of thiol disulfide couples such as cysteine and cysteine 
(Cys/CySS) and glutathione and glutathione disulfide (GSH and GSSG). 
Alterations in these thiol disulfide couples result in alterations in redox potential 
(Eh). Eh Cys/CySS exerts its main effects extracellularly, while Eh GSH/GSSH is 
more relevant intracellularly [376]. nAChRs could also play important roles in 
oxidant stress as the Roman lab recently reporting that a4 nAChRs might serve 
as sensors of Eh Cys/CySS in lung fibroblasts [377]. Additionally, our group has 
also reported that bleomycin-induced lung injury is associated with oxidation of the 
Eh Cys/CySS, which stimulates the proliferation of primary lung fibroblasts and 
their expression of a-smooth muscle actin and fibronectin, which are also 
hallmarks of IPF [378-381].  
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Elucidating Complicated Tobacco Smoke 
 
Having evaluated the role of a7 nAChRs in mediating the effects of nicotine, 
we have also explored the effects of cigarette smoke extract (CSE) on lung 
fibroblasts. As expected, CSE stimulated significant fibronectin protein production 
at 6 months (Figure 51 and Figure 52). With the myriad of chemicals in tobacco, it 
makes it difficult to elucidate the vast number of changes made by tobacco 
exposure, but recently a ‘smoking-lung-on-a-chip’ system has been developed, 
which provides a powerful tool to study the effects of whole cigarette and e-
cigarette smoke on lung cells [382].  
 
Tobacco-related Genetic Changes 
 
Advances in genetic technology have invigorated the focus of the scientific 
community on genetic and epigenetic changes driving diseases. The multifarious 
composition of tobacco causes a myriad of genetic changes [383]. Our lab is 
currently studying epigenetic changes caused by nicotine exposure, which could 
help to uncover genetic changes caused by nicotine. These changes could provide 








 Lung fibrosis has been associated with other diseases, including lung 
cancer [384]. In the Roman lab, Caleb Greenwell has done some work on the 
influence of pulmonary microenvironment on lung cancer, showing increased lung 
metastasis in the presence of pulmonary fibrosis (Figure 53) Additionally, over the 
course of my Ph.D., I conducted some research on lung cancer, consisting of a 
published review of the mammalian target of rapamycin (mTOR) in lung cancer 
and the potential for CRKL to mediate epithelial–mesenchymal transition, an 




Figure 51. Cigarette Smoke Induces Fibronectin In Vivo 
Roman et. Al. Unpublished 
(A) In collaboration with Douglas Arenberg at the University of Michigan, mice were 
exposed to tobacco smoke for up to 6 months (see methods). They were then 
sacrificed and the lungs processed for immunohistochemistry. A: anti-fibronectin 
antibody; B: Control IgG; C and D: Control lungs stained for fibronectin. E and F: 







Figure 52. Cigarette Smoke Induces Fibronectin Time-Dependently In Vivo 
Roman et. Al. Unpublished 
(A) Blinded evaluation of intensity of fibronectin staining at different stages. (B) 
Difference in fibronectin staining between control and CSE exposed mice as fold 








































































Figure 53. Bleomycin Treatment is Associated with Increased Metastases in 
Aged Lungs 
Greenwell et. Al. Unpublished 
(A) Aged (~9.5 months) mice were treated with PBS or bleomycin followed by 
injection with Lewis Lung Carcinoma cells. Lungs were inflated at standard 
pressure, fixed in formalin, paraffin-embedded, and sectioned (5 μm) for 
histological analysis. Representative images depict PBS- and bleomycin-treated 
aged mice at 14x magnification. Tumor metastases are observed in all images 
(indicated by arrows), while fibrosis is clear in the bleomycin treated lungs. (B) The 
number of lung metastasis was analyzed. Bleomycin instillation in aged animals 
increased the number of lung metastases compared to PBS. Significance was 
assessed using p values <0.05 obtained by two-tailed t-test. 
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